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Chronic lymphocytic leukemia (CLL) is a B-cell clonal lymphoprolipherative 
disorder characterized by the accumulation of small lymphocytes in the peripheral 
blood, bone marrow and lymph nodes deriving from the transformation of  CD5+ 
B-cell.  Despite a homogeneous immunophenotype consisting of CD19+, CD20+, 
CD5+ and CD23+, CLL is clinically heterogeneous. Several adverse prognostic 
features have been identified including stage, CD38 positivity, the unmutated 
configuration of the variable region of the immunoglobulin heavy chain gene 
(IGHV), ZAP70 positivity, chromosome aberrations and molecular abnormalities.  
 
Detailed immunophenotypic and genetic analysis allowed for the identification of a 
number of markers of activation and genetic instability, some of which are gaining 
relevance in clinical practice to predict outcome. Cell surface CD38 is one of these 
markers since it is an indicator of cell activation and proliferation that may prelude 
clonal evolution and worse clinical outcome.  
We therefore studied the biological and clinical significance of the presence of 
genetic heterogeneity in the minor CD38+ leukemic population, in a cohort of 
untreated low-risk CD38-negative CLL patients, defined by the presence of  <7% 
CD38+ cells, and by the absence of unfavourable genetic lesions. Our data 
showed that a significant proportion of CD38- CLL patients with low risk FISH 
findings presented genetic aberrations within CD38+ cells. Most of these 
abnormalities were high risk lesions (11q deletion and 17p deletion) and, in most 
of the cases, these lesions were found in different cells indicating that multiple 
cytogenetically unrelated minor clones may be present in the CD38+ cell fraction. 
Interestingly, the presence of these additional FISH lesions in the small CD38+ cell 
fraction was associated with shorter time to first treatment (TTT). To identify 
biomarkers associated with this phenomenon, we performed miRNA expression 
analysis. We were thus able to show a deregulated miRNA expression profile in 
CLL cases with additional FISH lesions in CD38+ cells. In particular, miR-125a-5p 
was found to be down-regulated both in CD38+ and CD38- cells in patients with 
FISH abnormal clones as compared to patients without FISH abnormal clones. 
The relevance of miR-125a-5p as a biomarker of inferior outcome and genetic 
complexity was then validated in a prospective cohort. In this validation cohort, we 
were able to confirm the predictive role of miR-125a-5p down-regulation in terms 
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of shorter TTT. In addition we found that CLL patients with lower levels of miR-
125a-5p displayed an increased rate of mutations in CLL-related genes by next-
generation sequencing. 
 
Several recent studies have shown that CD38 expression is higher in CLL cells in 
the bone marrow and lymphoid tissues, especially in the proliferation centres 
(PCs), which are regarded as the histologic hallmark of this disease. Indeed CLL is 
a disease in which the host’s microenvironment promotes leukemic cell growth, 
leading to sequential acquisition and accumulation of genetic alterations and 
proliferation centers may play an important role in the biology of CLL, as they 
represent  its proliferative compartment. To better deﬁne the signiﬁcance of 
proliferation centers, we studied lymph node biopsies taken from a cohort of 
patients by ﬂuorescence in situ hybridization (FISH) studies using a 5-probe panel 
on tissue microarrays (TMA). The cases were classified into two categories: “PCs-
rich” and “typical”. The PCs-rich group was associated with 17p-, 14q32/IGH 
translocations and +12. The median survival from the time of TMA for PCs-rich 
and typical groups was 11 and 64 months respectively. The PCs-rich pattern was 
the only predictive factor of an inferior survival. These findings establish an 
association between cytogenetic profile and the amount of PCs in CLL, and show 
that this histopathologic characteristic is of value for risk assessment in patients 
with clinically significant adenopathy. 
 
CLL turned out to be a disease with multiple facets in its pathogenic mechanisms 
including genetic aberrations, antigen drive and microenvironmental interactions. 
In the first part of this work, we focused our attention on the correlation between 
CD38-positivity, proliferation centres and development of genetic aberrations.  
To translate this knowledge in clinical practice we planned further studies focusing 
i) on the correlation between chromosomal aberrations and clonal evolution and ii) 
on how to stratify patients into different risk-groups at diagnosis according to 
cytogenetic abnormalities and gene mutations. 
The presence of cytogenetic abnormalities is a hallmark of CLL. It was reported 
that a fraction of CLL patients developed new cytogenetic abnormalities at 
chromosome sites of known prognostic importance during the course of their 
disease (clonal evolution, CE). To better define the incidence and signature of CE, 
a cohort of patients were analysed sequentially by FISH. Recurring aberrations at 
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clonal evolution were 14q32/IGH translocation, 17p-, 11q-, 13q- and 14q32 
deletion. The development of CE occurred only in previously treated patients. Our 
data show that the 14q32/IGH translocation may represent one of the most 
frequent aberrations acquired during the natural history of CLL. CE occurs in pre-
treated patients with short TTT and survival, after the development of CE with and 
without 14q32 translocation, is relatively short. 
 
Having assessed the incidence of chromosome aberration in CLL with evolution 
and/or adenopathy we next moved to CLL with an apparently “favourable” profile 
of cytogenetic lesions, to establish if improved cytogenetic techniques could help 
refine prognostication. We therefore designed a study to assess whether 
karyotypic aberrations in patients without FISH anomalies correlate with 
established clinical and prognostic parameters. The clinical and prognostic 
significance of karyotypic aberrations in normal FISH CLL was first evaluated in a 
retrospective single centre series of patients and then validated prospectively in a 
multicentre series of cases diagnosed and analysed for karyotype with DPS30/IL2 
stimulation. Conventional karyotyping using DSP30/IL2 stimulation is an effective 
method for the detection of chromosome aberrations in approximately one third of 
CLL with normal FISH. The abnormal karyotype correlated with shorter time to first 
treatment and shorter survival. This set of data also showed that, in CLL patients 
with normal FISH, conventional cytogenetic analysis identifies a subset of cases 
with adverse clinical and prognostic features to be considered for the design of 
risk-adapted treatment strategies. 
In the last part of our experimental work we moved from the consideration that the 
cytogenetic lesions do not entirely explain the molecular pathogenesis and the 
clinical heterogeneity of CLL. Indeed, the advent of next-generation sequencing 
(NGS) technologies has enabled exploration of the CLL genome, uncovering 
genetic lesions that recurrently target the leukemic cells. NGS studies have further 
elucidated the genomic complexity of CLL. In order to improve understanding of 
genetic basis of CLL and to apply NGS to CLL, we sequenced DNA samples from 
untreated patients affected by chronic lymphocytic leukemia with a panel of 20 
genes and we correlated mutational status with clinicobiological 
parameters.Mutations were identified in the following genes: TP53, SF3B1, POT1 , 
ATM , MYD88 , FBXW7 , MAPK1 , DDX3X , KLHL6 , KRAS. The presence 
of mutations correlated with high risk FISH (11q- and/or 17p-) and unfavourable 
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cytogenetic (11q-, 17p- or complex karyotype) findings. Patients carrying CLLs 
with gene mutations showed a significant shorter median time to first treatment in 
comparison to those without mutations (20 months vs not reached at 76 months). 
The frequency of mutations in the 20 investigated genes is in line with published 
data in the literature using whole exome sequencing. This study shows that the 
simultaneous sequencing of a panel of genes implicated in CLL is feasible. 
 
In conclusion, in this work we tried to improve our knowledge on some 
fundamental pathogenetic aspects of CLL, including: 
i) the development of genetic lesions in CD38+ activated cells, obtained 
from the PB in patients in an initial and indolent phase of the disease; 
ii) the pattern of cytogenetic lesions in lymph node microenvironment 
(proliferation centres) in patients in a more advanced phase of the 
disease; 
iii) to translate this knowledge in clinical practice, we assessed prognosis 
with modern techniques and we identified cytogenetic lesions 
associated with disease progression and shorter time to treatment; 
iv) we identified recurrent genetic lesions potentially useful for further 






La leucemia linfocitica cronica (LLC) è un disordine linfoproliferativo a carico del 
linfocita B, caratterizzato dall’accumulo di piccoli linfociti nel sangue periferico, nel 
midollo osseo e nei linfonodi. Nonostante un immunofenotipo omogeneo costituito 
dalla presenza degli antigeni CD19, CD20, CD5  e CD23, la LLC è clinicamente 
eterogenea. Sono stati identificati diversi fattori di prognosi. Tra questi ritroviamo 
lo stadio di malattia alla diagnosi, la positività per il CD38, la configurazione non 
mutata della regione variabile della catena pesante dei geni immunoglobulinici 
(IGHV), la positività per ZAP70, le aberrazioni cromosomiche e le anomalie 
molecolari. 
 
Analisi immunofenotipiche e genetiche hanno portato all'identificazione di diversi 
marcatori molecolari di attivazione, alcuni dei quali sono riconosciuti nella pratica 
clinica al fine di predire la prognosi. L’antigene di superficie CD38 è uno di questi. 
Esso, in particolare, è un indicatore di prognosi sfavorevole, di attivazione e 
proliferazione cellulare ed è in grado di predire un’evoluzione clonale ed una 
prognosi sfavorevole.  
Abbiamo quindi studiato, in un gruppo di pazienti a basso rischio (cellule CD38+ 
<7% e anomalie FISH a basso rischio prognostico), il significato biologico e clinico 
della presenza di lesioni genetiche nella frazione cellulare CD38 positiva. I nostri 
dati hanno mostrato che una percentuale significativa di pazienti presentano 
aberrazioni genetiche all'interno delle cellule CD38+. La maggior parte di queste 
anomalie sono lesioni ad alto rischio (delezione 11q e 17p) e nella maggior parte 
dei casi queste lesioni sono stati trovate in cellule diverse indicando che più cloni 
minoritari possono essere presenti, in maniera indipendente, nella popolazione 
cellulare complessiva. La presenza di queste lesioni FISH nella piccola frazione 
CD38+ è associata ad un minore tempo al primo trattamento (TTT). Per 
identificare marcatori associati a questo fenomeno, abbiamo effettuato un’analisi 
di espressione dei microRNAs. Abbiamo quindi identificato un profilo di 
espressione dei miRNAs alterato nei casi di LLC con lesioni FISH supplementari a 
carico delle cellule CD38+. In particolare, il miR-125a-5p è risultato essere down-
regolato sia nelle cellule CD38+ che nelle cellule CD38- nei pazienti con cloni 
aventi anomalie FISH, rispetto ai pazienti senza cloni anomali. L’importanza del 
miR-125a-5p come marcatore di prognosi inferiore e complessità genetica è stata 
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poi validata in una coorte di pazienti indipendente. In questa serie di validazione, 
abbiamo confermato il ruolo predittivo del miR-125a-5p in termini di TTT più breve. 
Inoltre abbiamo visto, attraverso tecniche di sequenziamento di ultima 
generazione, che i pazienti affetti da LLC con bassi livelli di miR-125a-5p 
presentano un aumento del tasso di mutazione nei geni implicati nella LLC. 
 
Diversi studi recenti hanno dimostrato che l'espressione del CD38 è maggiore 
nelle cellule leucemiche all’interno del midollo osseo e del tessuto linfoide, in 
particolare all’interno dei centri proliferativi (PCs), che sono considerati la 
peculiarità istologica della LLC. Infatti la LLC è una malattia in cui microambiente 
promuove la crescita delle cellule leucemiche, conduce all'acquisizione ed al 
conseguente accumulo di alterazioni genetiche. In questo contesto, i centri 
proliferativi svolgono un ruolo fondamentale. 
Per definire meglio il significato dei PCs, abbiamo studiato le biopsie linfonodali di 
una coorte di pazienti con metodica FISH su microarray tissutale (TMA). I casi 
sono stati classificati in due categorie: "PC-rich" e "tipici". Il gruppo “PC-rich” è 
stato associato alla presenza di delezioni 17p-, traslocazioni 14q32/IGH e trisomia 
del cromosoma 12. La sopravvivenza media, dal momento del TMA, per i gruppi 
“PC-rich” e “tipici” è risultato essere, rispettivamente, di 11 e 64 mesi. Questi 
risultati stabiliscono, quindi, un'associazione tra il profilo citogenetico e la quantità 
di PCs nella LLC, e dimostrano che questa caratteristica istopatologica è di grande 
valore per la valutazione del rischio nei pazienti con adenopatie clinicamente 
significative. 
 
La LLC si è rivelata essere una patologia con molteplici sfaccettature nei suoi 
meccanismi patogenetici, tra cui la presenza di aberrazioni genetiche, la 
stimolazione da parte dell’antigene e le interazioni con il microambiente. Nella 
prima parte di questo lavoro, abbiamo focalizzato la nostra attenzione sulla 
correlazione tra positività per il CD38, centri proliferativi e sviluppo di aberrazioni 
genetiche. Per tradurre queste conoscenze nella pratica clinica abbiamo 
programmato ulteriori studi incentrati i) sulla correlazione tra aberrazioni 
cromosomiche e l'evoluzione clonale e ii) su come stratificare i pazienti in diversi 




La presenza di anomalie citogenetiche è un segno distintivo della LLC. In 
letteratura è riportato che una frazione di pazienti affetti da LLC sviluppa  nuove 
anomalie citogenetiche durante il corso della malattia (evoluzione clonale, CE). 
Per definire meglio l'incidenza e lo stato dell’evoluzione clonale, abbiamo 
analizzato una coorte di pazienti mediante FISH a diversi stadi di malattia. 
Aberrazioni ricorrenti nell’evoluzione clonale sono risultate essere: traslocazioni 
14q32/IGH, delezioni 17p-, 11q-, 13q-e 14q32. L’evoluzione clonale si è verificata 
solo in pazienti precedentemente trattati. I nostri dati mostrano che la 
traslocazione 14q32/IGH rappresenta una delle aberrazioni acquisite più frequenti 
durante la storia naturale della LLC. Il fenomeno dell’evoluzione clonale si verifica 
in pazienti pretrattati con breve TTT, e la sopravvivenza dopo lo sviluppo di 
evoluzione clonale è relativamente breve. 
 
Dopo aver valutato l'incidenza di aberrazioni cromosomiche in pazienti LLC con 
evoluzione clonale e/o adenopatia, ci siamo soffermati sul gruppo di pazienti LLC 
con lesioni citogenetiche "favorevoli".  Abbiamo, quindi,  effettuato uno studio per 
valutare se le aberrazioni cromosomiche in pazienti FISH negativi correlino con i 
parametri clinici e prognostici. Abbiamo dapprima studiato una coorte retrospettiva 
di pazienti aventi le suddette caratteristiche. In seguito, abbiamo validato 
prospetticamente in una serie multicentrica di casi analizzati mediante cariotipo 
convenzionale con stimolazione metafasica attraverso DPS30/IL2. Abbiamo visto 
che questa tecnica permette l'individuazione di aberrazioni cromosomiche in circa 
un terzo dei casi LLC con FISH normale. Il cariotipo anomalo correla con un 
minore tempo al primo trattamento ed una ridotta sopravvivenza. Questo insieme 
di dati ha quindi mostrato che, nei pazienti affetti da LLC con FISH normale, 
l'analisi citogenetica convenzionale identifica un sottoinsieme di casi con 
caratteristiche cliniche e prognostiche negative da prendere in considerazione al 
fine di adeguare le strategie di trattamento. 
 
Nell'ultima parte del nostro lavoro sperimentale, abbiamo considerato che le 
lesioni citogenetiche non sono in grado di spiegare la patogenesi molecolare e 
l'eterogeneità clinica della LLC. L'avvento del sequenziamento di ultima 
generazione (NGS) ha permesso l’acquisizione di importanti conoscenze sulla 
caratterizzazione della LLC, chiarendone ulteriormente la complessità genomica. 
Al fine di migliorare la comprensione delle basi genetiche delle LLC e di applicare 
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le tecniche di NGS, abbiamo sequenziato una serie di pazienti non trattati con un 
pannello di 20 geni, ritrovati frequentemente mutati nella LLC, e abbiamo correlato 
lo stato mutazionale con i parametri clinicobiologici. Abbiamo ritrovato mutazioni 
somatiche nei seguenti geni: TP53, SF3B1, POT1, ATM, MYD88, FBXW7, 
MAPK1, DDX3X, KLHL6, KRAS. La presenza di mutazioni correla con la presenza 
di anomalie FISH ad alto rischio (11q- e/o 17p-), e cariotipo sfavorevole (11q-, 17p 
o cariotipo complesso). Pazienti recanti mutazioni genetiche hanno mostrato un 
tempo al trattamento significativamente più corto rispetto a quelli senza mutazioni. 
La frequenza di mutazioni nei 20 geni studiati è in linea con i dati pubblicati in 
letteratura. 
  
In conclusione, in questo lavoro abbiamo cercato di migliorare le nostre 
conoscenze su alcuni aspetti patogenetici fondamentali della LLC, tra cui: 
i) lo sviluppo di lesioni genetiche in cellule attivate CD38+, ottenute da 
sangue periferico in pazienti in una fase iniziale e indolente di malattia; 
ii) il tipo di lesioni citogenetiche nel microambiente linfonodale (centri 
proliferativi) in pazienti in una fase più avanzata di malattia; 
iii) traducendo queste conoscenze nella pratica clinica, abbiamo valutato la 
prognosi con tecniche moderne ed identificato lesioni citogenetiche 
associate a progressione di malattia e minor tempo libero da trattamento; 
iv) abbiamo identificato lesioni genetiche ricorrenti potenzialmente utili per un 
ulteriore affinamento della nostra capacità di predizione della prognosi e 










Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in 
Western countries and is characterized by clonal proliferation and accumulation of 
mature B lymphocytes. CLL affects individuals with median age at diagnosis 
ranging between 67 and 72 years. Moreover, the proportion of younger patients 
with early stage CLL and minimal symptoms seems to increase due to more 
frequent blood testing. More male than female patients (1.7:1) are affected [1]. 
CLL is characterized by the clonal proliferation and accumulation of mature, 
typically CD5-positive B-cells within the blood, bone marrow, lymph nodes and 
spleen [2]. Typical immunophenotype of the CLL is the presence of the B-cell 
surface antigens CD19, CD22 and CD 23 with coexpression of T-cell lineage 
antigen CD5 and expression of CD20 and CD7b lower than that observed in 
normal B cells [3, 4]. 
 
1.2 DIAGNOSIS AND STAGING 
The diagnostic criteria as laid out by the International Workshop on Chronic 
Lymphocytic Leukemia (IWCLL-2008) [4] requires the presence of at least  5.000 
B-lymphocytes/ul in the peripheral blood for the duration of minimum 3 months. In 
most cases the diagnosis of CLL is established by blood counts, differential 
counts, a blood smear and immunophenotyping. The World Health Organizaton 
(WHO) classification of hematopoietic neoplasias describes CLL as leukemic, 
lymphocytic lymphoma, being only distinguishable from SLL (small lymphocytic 
lymphoma) by its leukemic appearance [5].  
CLL is always a disease of neoplastic B-cells and their clonality needs to be 
confirmed by flow cytometry [4]. The leukemia cells found in the blood smear are 
characteristically small, mature lymphocytes with a narrow border of cytoplasm 
and a dense nucleus lacking discernible nucleoli and having partially aggregated 
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inhibition of apoptosis is responsible for CLL development. However, several 
reports have shown that the high lymphocyte count in CLL patients is caused not 
only by the prolonged survival, but also by proliferating cells. The disease probably 
develops is a result of accumulation of transformed B cells. In CLL cells, a great 
imbalance between cell birth and death rate is observed [3, 9]. 
The gene expression profile suggests that CLL cells originate from transformed, 
antigen-stimulated B cells [10]. In CLL cells, several mutated IGHV genes are 
expressed more frequently than in normal B lymphocytes. All those cells express 
restricted sets of B-cell receptors (BCR). Unique stereotypy of BCR suggests that 
antigens play a critical role in CLL pathogenesis. 
Moreover, CLL has recently been established as a disease of remarkable diversity 
and differences in cell morphology, immunophenotype, cytogenetics and 
molecular characteristics. This heterogeneity translates into clinical course and the 
response to treatment [11].  Approximately one third of patients survive for 20 
years or longer and never require treatment [12] and, alternatively, some patients 
may progress rapidly from the time of diagnosis. 
 
1.4 PROGNOSTIC FACTORS IN CLL 
A number of clinical and biological markers of prognostic relevance have been 
identified. Due to great variability of CLL patients clinical course, there is a need to 
establish solid prognostic factors for this disease. 
CLL patients are currently categorized into risk groups based on the clinical 
staging systems Rai [7] and Binet [8]. These classifications are helpful for dividing 
patients in regard to the expected overall survival (OS). However, both systems 
fail to indicate the higher risk of progression among patients in early stage of 
disease. 
Among prognostic factors in CLL, there are lymphocyte doubling time (LDT), 
serum markers, IGHV mutational status, ZAP-70 and CD38 expression, 
cytogenetic abnormalities and somatic mutations [13-16]. 
LDT longer than 12 months correlates with increased progression-free survival 
(PFS) and OS. An increase in the lymphocyte count of more than 50% in two 
months or LDT during less than 6 months is a recommended criterion of active 



































































































































































Similar correlation with outcome has been shown for CD38 expression. CD38-
positive patients (the threshold proposed is >30% CD38+ CLL cells) were reported 
to have significantly worse prognosis regarding PFS and OS than those who were 
CD38 negative. It was observed that CD38 expression on CLL cells correlates with 
the absence of IGHV mutations [3, 4, 13, 18, 19]. 
A crucial prognostic importance is assigned to chromosomal aberrations. In 
approximately 80% of patients, there is a mutation detected by fluorescence in situ 
hybridization (FISH) [15]. The most common recurrent chromosomal abnormalities 
include deletion 13q, trisomy 12 and deletions 11q, 17p and 6q. A subdivision 
based on these aberrations is important, as they are predictor of disease outcome. 
Five prognostic categories have been identified in a hierarchical model, showing 
poor survival in patients with 17p deletion or 11q deletion (median survival 32 and 
79 months, respectively) but better survival for patients with trisomy 12, normal 
karyotype, and deletion 13q as the sole abnormality (114, 111 and 133 months, 
respectively) [15]. Deletions of 11q22-q23 and 17p13, resulting in abnormalities of 
ATM and TP53 genes, respectively, are independent prognostic factors identifying 
patients with a rapid disease progression and a short OS in a multivariate analysis. 
Patients with del(11q) have more frequently B symptoms, advanced clinical stage 
and extensive peripheral, abdominal and mediastinal lymphoadenopathy. 
Deletions 17p and 11q are more often detected in advanced stages of the disease, 
among patients with unmutated IGHV gene. In contrast, deletion of chromosome 
band 13q14 is associated with a favourable CLL outcome. Moreover, patients with 
trisomy 12 have a shorter OS than those with 13q deletion [3, 4, 9, 13, 15, 18]. 
TP53 mutations have been described in 4-12% of patients with untreated CLL. 
Approximately 80-90% of cases with a deletion of one copy of TP53 locus will 
have a TP53 mutation on the remaining copy [16, 20-23]. TP53 mutations are 
more prevalent in progressive and refractory CLL [22] (Fig 1.3). A TP53 mutation 
is an independent predictor of poor prognosis and confers even shorter OS than 
del(17p) in the absence of TP53 mutation [20]. Mutations of the ATM gene may 
also have prognostic implications independent of those associated with the 
deletion of chromosome 11q. Patients harbouring ATM mutations have a more 
aggressive clinical course and are more resistant to traditional chemotherapeutic 
agents [24, 25]. 
In recent times, the improvements in next generation sequencing technologies 
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1.5.1 Cytostatic Agents 
For many years, chlorambucil (with or without steroids) was the drug of choice in 
previously untreated patients with progressive or advanced CLL [31]. Even today, 
this drug remains an appropriate option for elderly and unfit patients. The 
advantages of chlorambucil are its moderate toxicity and low cost; the major 
disadvantages are its low complete remission (CR) rate and some side effects that 
occur after extended use. 
Three purine analogs are currently used in CLL: fludarabine, pentostatin and 
cladribine. These drugs showed high antileukemic activity. Significantly higher 
overall response (OR), complete remission and progression free survival (PFS) in 
patients treated with fludarabine or cladribine were documented in several 
randomized clinical trials [32, 33]. Next, combination of fludarabine or cladribine 
with cyclophosphamide appeared to be more effective than purine analogs in 
monotherapy in regard to OR, CR and PFS [34-36]. 
 
 1.5.2 Antibodies 
Rituximab. CD20 is an activated, glycosylated phosphoprotein expressed on 
the surface of mature B-cells. The protein has unknown natural ligand and its 
function is not yet discovered [37]. As CD20 is expressed on most B-cell 
malignancies, the introduction of the anti-CD20 antibody Rituximab in 1998 
improved the treatment of most CD20-positive on-Hodgkin lymphomas including 
CLL [38]. In CLL, Rituximab is less active as single agent than in follicular 
lymphoma, unless very high doses are used [39, 40]. In contrast, combinations of 
Rituximab and chemotherapy have proven to be very efficacious therapies of CLL. 
Ofatumumab. It is a fully humanized antibody targeting a unique epitope on the 
CD20 molecule expressed on human B-cells. Ofatumumab was found to be 
effective in a phase III randomized study, as monotherapy for heavily pretreated 
patients with CLL resistant to fludarabine or fludarabine-alemtuzumab regimen 
[41]. 
Alemtuzumab. It is another MoAb, recombinant, humanized anti-CD52, highly 
active in CLL. In previously untreated patients, an OR rate of more than 80% was 
achieved, being effective in patients with high risk genetic markers such as 
deletions of chromosome 11 or 17 and TP53 mutations [42, 43], and in those 
patients with Alemtuzumab can be used as a first-line treatment [44]. 
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Obinutuzumab (GA101). The humanized and glycol-engineered monoclonal 
antibody Obinutuzumab showed impressive results in vitro with higher rates of 
apopotosis in B-cells in comparison to Rituximab [45]. Encouraging results were 
reported in the interim analysis of CLL11 trial on CLL patients with comorbidity. 
The primary endpoint was PFS [46]. 
 
 1.5.3 Combination chemotherapy 
A major advance in CLL treatment was achieved by the combined use of different 
treatment modalities. Because purine analogs and alkylating agents have different 
mechanisms of action and partially nonoverlapping toxicity profiles, they were 
combined to achieve synergistic effects. The most thoroughly studied combination 
chemotherapy for CLL is fludarabine plus cyclophosphamide (FC) [47]. In 
noncompertive trials, the overall response rates did not appear to be better than 
with fludarabine alone, but the addition of cyclophosphamide appeared to improve 
the CR rate up to 50% [47]. A phase II study of cladribine in combination with 
cyclophosphamide has also demonstrated activity in advanced CLL, but results 
seemed inferior to FC [48]. 
 
1.5.4 Chemoimmunotherapy 
The results of recent studies showed that Rituximab in combination with purine 
analogs or purine analogs and cyclophosphamide can increase the OR and CR 
rates and PFS time [49]. The combination of Rituximab with FC (FCR regimen) 
demonstrated particularly high rates of OR, CR and duration of PFS in both 
previously untreated and relapsed/refractory CLL [50]. However FCR is acceptable 
for younger, physically fit patients. This regimen has limitations in the unfit group, 
mainly due to the risk of myelosuppression and other side effects. Because CLL 
often occurs in elderly patients with relevant comorbidities, a dose modified FCR-
Lite regimen was designed to maintain the efficacy but decrease the toxicity of the 
FCR regimen [51]. This regimen reduced the dose of fludarabine and 
cyclophosphamide and increased the dose of Rituximab. Recent trials proved that 
combination of Rituximab with pentostatin or cladribine and cyclophosphamide is a 
highly active treatment modality in CLL. More recently, bendamustine, a 
bifunctional agent composed of an alkylating nitrogen mustard group and a purine-
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like benzimidazole ring, has been included in CLL treatment regimens. In a 
randomized trial compared activity of bendamustine or chlorambucil in untreated 
CLL patients [52], OR and CR rates were significantly higher in patients treated 
with bendamustine. Several other combinations have been investigated, such as, 
cladribine with rituximab, methylprednisolone plus rituximab followed by 
alemtuzumab, or rituximab plus alemtuzumab. 
 
1.5.5 New drugs targeting pathogenic pathways of CLL cells 
There are an increasing number of interesting new compunds in clinical 
development. The common denominator of these compounds is that thei 
mechanism of action targets a relatively specific signalling abnormality or redirects 
the immune system against CLL cells. 
Agents targeting BCR signalling. Idelalisib (CAL-101) is an inhibitor of 
phosphatidylinositol 3-kinase (PI3K) signalling. CAL-101 reduces survival signals 
derived from the BCR and inhibits BCR and chemokine-receptor-induced AKT and 
MAP kinase (ERK) activation [53]. In preclinical studies, it was found to induce 
apoptosis of CLL cells. Protein kinase C and PI3K pathways have an influence on 
the survival of B cells in CLL. In a phase I clinical trial, Idelalisib showed 
acceptable toxicity, positive pharmacodynamics effects and favourable clinical 
activity [54]. Results on Idelalisib in combination with Rituximab, Ofatumumab or 
bendamustine/rituximab were presented in preliminary form and showed 
encouraging results . 
Ibrutinib is an orally active small molecule inhibiting BTK that plays a role in the 
signal transduction of the BCR. Inhibition of BTK might induce apoptosis in B-cell 
lymphomas and CLL cells [55]. Ibrutinib showed significant activity in patients with 
relapsed or refractory B-cell malignancies, including CLL [56].  
Bcl-2 inhibitors. Proteins in the B-cell CLL/Lymphoma 2 (Bcl-2) family are 
key regulators of the apoptotic process [57]. The Bcl-2 family comprises 
proapoptotic and prosurvival proteins. Shifting the balance toward the latter is an 
established mechanism whereby cancer cells evade apoptosis. ABT-263 
(Novitoclax) is a small molecule Bcl-2 family inhibitor that binds with high affinity to 
multiple antiapoptotic Bcl-2 family proteins. Initial studies showed very promising 
results for this drug as single agent [58]. However its therapeutic use seemed 
somewhat limited by severe thrombocytopenia being a prominent side effect. 
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Therefore the compound was reengineered to create a highly potent and cl-2 
selective inhibitor, ABT-199 [59]. This compound inhibits the growth of Bcl-2-
dependent tumors in vivo and spares human platelets. Recent data from clinical 
trials indicate that selective pharmacological inhibition of Bcl-2 holds great promise 
for the treatment of CLL. 
 
Given the impressive choice of options, the right choice of treatment becomes  a 
task that requires experience, a good clinical judgement and an appropriate use of 
diagnostic tools. The following parameters should be considered before 
recommending a treatment for CLL: the clinical stage of disease; the fitness of the 
patient; the genetic risk of leukemia; the treatment situation (first versus second 










In 1995, chronic lymphocytic leukemia (CLL) was defined as a homogeneous 
disease of immature, immune-incompetent, minimally self-renewing B cells [2], 
which accumulate relentlessly because of a faulty apoptotic mechanism. Since ten 
years, these views have been transformed by a wealth of new information about 
the leukemic cells. CLL is currently considered a clinically heterogeneous disease 
originating form B lymphocytes that may differ in activation, maturation state or 
cellular subgroup. Leukemic cell accumulation occurs because of survival signals 
delivered to a subgroup of leukemic cells from the external environment through a 
variety of receptors and their cell-bound and soluble ligands [60]. 
CLL is seen as a disease characterized by a dynamic balance between cells 
circulating in the blood and cells located in permissive niches in lymphoid organs 
[61]. The former are primarily mature-looking small lymphocytes resistant to 
apoptosis, whereas the latter are composed of lymphocytes that undergo either 
proliferation or apoptosis according to environment [60]. 
 
B lymphocytes mature in the bone marrow and in the process rearrange 
immunoglobulin variable (V) gene segments to create the code for an 
immunoglobulin molecule that serves as the B-cell receptor for antigen. When an 
antigen of adequate affinity engages the receptor, the cell enters a germinal center 
in lymphoid follicles, where, as a centroblast, it rapidly divides and its V genes 
undergo somatic hypermutation. This process introduces mutations in the 
rearranged VHDJH and VLJL gene segments that code for the binding site of the 
receptor. Through these mutations, the receptors of the descendent B cells, called 
centrocytes, acquire new properties. Centrocytes with receptors that no longer 
bind the antigen or do bind autoantigens are normally eliminated [62]. 
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This stimulation and selection pathway usually requires the help of T lymphocytes 
and occurs in germinal centers [62], the structure of which ensures the selection of 
B cells capable to recognize antigens. However, the process can proceed without 
T cells [63] and outside germinal centers, in the marginal zones around lymphoid 
follicles [64]. Both process lead to the development of plasma cells or memory 
(antigen-experienced) B cells. Concomitant with B-cell activation, the proteins on 
the surface of the B cell change. These modifications help activated B cells to 
interact with other cells and soluble mediators. One surface molecule that supports 
B cell interactions and differentiation is CD38 [65]. 
The heterogeneous clinical outcome of CLL patients is dictate, at least in part, by 
the nature of these microenvironmental signals and interactions that can promote 
or impair accumulation of genomic alterations [66]. Detailed immunophenotypic 
and genetic analysis of different neoplastic clones have led to the identification of 
a number of molecular markers of activation, some of which are gaining relevance 
in clinical practice to predict outcome [14, 15, 17, 67]. Cell surface CD38 is one of 
these markers. 
 
2.2 CD38 IS ASSOCIATED WITH GENETIC HETEROGENEITY AND 
CLONAL EVOLUTION 
2.2.1 Biology of human CD38 
CD38 is expressed at high levels by B lineage progenitors in bone marrow and by 
B lymphocytes in germinal center, in activated tonsils, and by terminally 
differentiated plasma cells [68]. On the other side, mature virgin and memory B 
cells express low levels of this molecule. CD38 is located in the cytosol and/or in 
the nucleus and not on the cell membrane [68]. 
CD38 is a 45 kDa type II transmembrane glycoprotein. The functional CD38 
molecule is a dimer, with the central part hosting the catalytic site [69]. The 
transition from monomer to dimer modulates the function of the molecule. CD38 
has the tendency to associate with other proteins, forming large supramolecular 
complexes. Molecules that associate with CD38 include the CD19/CD81 complex, 
the chemokine receptor CXCR4, ad adhesion molecules, such as CD49d [70, 71]. 
CD38 is also found in exosomes [72], membrane vescicles secreted by B cells, 
and is probably part of an intracellular communication network. 
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The functional properties of CD38 on human B cells appear to be strictly linked to 
the stage of maturation. The presence of blocking mAbs in cultures of CD19+ B-
cell precursors on stromal layers markedly suppress B-cell lymphopoiesis by 
inducing apoptosis [73]. In contrast, in mature circulating B lymphocytes and 
tonsillar germinal center B cells, CD38 ligation is followed by activation, apoptosis 
inhibition, proliferation and cytokine secretion [74, 75]. In both cases, the 
mechanisms are attributed to the activation of an intracellular signalling pathway 
ruled by CD38 and requiring an association with CD19. 
 
2.2.2 CD38 as a marker in CLL 
CD38 identifies two subgroups of CLL patients with different clinical outcomes 
[67]; this distinction is based on the percentage of CD38+ leukemic cells within a 
CLL clone. The two patient subgroups differ clinically in several ways, including 
overall survival [67, 76], time to first treatment [77, 78], number of leukemic cells 
with atypical morphology [79], extent and level of adenopathy [76] and absolute 
lymphocyte counts [80]. These subgroups also differ in responsiveness to various 
therapies [80]. 
The past decade has highlighted several molecular differences between CD38+ 
and CD38- members of the same clone, including expression of specific activation 
markers [81], which reflect quantitative and temporal differences in response to 
stimulation. CD38+ CLL cells express high levels of CD69 and HLA-DR [82], both 
indicative of recent activation. CD38 also marks a cellular subset enriched in Ki-
67+ and ZAP-70+ cells. In addition, CD38+ CLL clones display enhanced ability to 
migrate in response to chemokine and to transduce BCR-mediated signals. 
These findings suggest that cellular proliferation might be at the root of the 
association between higher levels of CD38, aggressively growing CLL clones, and 
poor patient outcome [60]. This suggestion is consistent with in vivo labelling 
experiments using 2H2O (“heavy water”) that demonstrated larger than anticipated 
rates of CLL birth, especially in patients with poor clinical course and outcome [83] 
and  a several-fold higher percentage of newly born cells in CD38+ fractions of 
CLL clones than in CD38- counterparts of the same clones [84]. Furthermore, 
preliminary results from a large clinical study suggest that the percentage of 
CD38+ CLL cells strongly correlates with the level of leukemic cell turnover 
observed in vivo [85]. 
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2.2.3 CD38 and genetic subclonal complexity 
Current models of cancer progression are based on the concept that tumors are 
subject to the Darwinian process of evolution and selection. Recent studies in 
acute lymphpoblastic leukemia have provided pivotal insights into the complex 
sequence of events during leukemogenesis, showing that the initiating mutation is 
followed by copy number alterations (CNAs) that drive the emergence of the 
disease [86, 87]. These data imply that at least some CNAs/copy neutral loss of 
heterozigosity regions (cnLOHs) are likely to be involved in driving leukemia 
progression and therefore might contribute to relapse. Knight and colleagues [88] 
hypothesized that subclones containing driver CNAs/cnLOHs would newly occur 
or expand in relapse samples compared with samples taken before treatment. 
They tested their hypothesis by systemically tracking the presence and subclonal 
distribution of CNAs/cnLOHs in CLL patients before treatment and at subsequent 
relapse. The results reveal complex changes in the subclonal architecture of 
paired samples at relapse compared with pre-treatment, suggested that genomic 
complexity correlate with a poor clinical outcome. Clinically, the existence of 
multiple, genetically distinct, subpopulations that escape therapeutic intervention 
might present formidable challenges for the development of effective treatment for 
patients with relapsed refractory CLL. 
In order to better understand the ongoing evolution of genetic lesions in patients 
with CLL, Grubor and colleagues [89] compared the leukemic genome with the 
patient’s normal DNA by using a high-resolution CGH technique called 
representational oligonucleotide microarray analysis (ROMA) [90]. This technique 
have an incredible resolution and it is so sensitive to permits the examination of 
the clonal heterogeneity within the same CLL patient form mixed population. To 
find clearer evidence of intraclonal heterogeneity within patients, they searched for 
genomic differences between CD38+ and CD38- populations in the same patient. 
So they profiled the genomes of CLL cells separated by the surface marker CD38 
and found evidence of distinct subclones of CLL within the same patient. In fact, 
they observed copy number differences between CD38+ and CD38- fractions in 3 
of 4 cases. In one case, this involved a loss of p53 locus in the CD38+ fraction, a 
marker that was not observed in the parallel CD38- fraction. 
Another molecular basis for the association between CD38 expression and inferior 
clinical outcome emerged in the study of Pepper and colleagues [91]. They 
analysed sorted CD38+ and CD38- CLL cells derived from the same patient by 
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gene expression profiling. Their conclusion is that CD8+ fraction possess a distinct 
gene expression profile when compared with CD38- subclones. Subclonal 
populations, having identical IgHV rearrangements, derive from a single malignant 
transforming event and differences in gene expression between them cannot be 
explained by heterogeneous genetic background. Importantly, CD38+ CLL cells 
relatively over expressed vascular endothelial growth factor (VEGF). Elevated 
VEGF expression was associated with increased expression of the anti-apoptotic 
protein Mcl-1. Moreover, the expression of the CD38 antigen defines a sub-
population of CLL cells with a distinct transcriptional profile that may be the cause 
or effect of an increase in cellular activation and reduced apoptosis. 
More generally, within an overall apparently constant leukemic burden, the 
outgrowth of a subclone with additional genomic lesions and distinct gene 
expression profile might signal the start of a new phase of the disease. 
 
In order to better understand the biological and molecular features predicting 
disease progression in CLL patient, we choose a subset of patients with 
favourable prognostic features and designed a two-phase study having the 
following aims: 
- Phase I, a) to assess whether genetic lesions may be present in the 
minority of CD38+ cells in a series of untreated low risk patients as defined 
by CD38 negativity (CD38+ cells <7%) and favourable genetic findings 
b) to identify biologic factors associated to genetic lesions in the small 
CD38+ fraction of CD38- CLL patients and predicting for disease 
progression; 
- Phase II, to validate our findings in an independent cohort of consecutive 
untreated CD38- CLL patients with favourable FISH findings. 
Details are shown in Appendix I (paper Rigolin GM et al., Oncotarget 2013). 
 
2.2.4 Methods and results 
2.2.4.1 Patients 
In this study 2 cohorts of patients have been considered. Cohort one (C1) included 
28 untreated CLL patients seen between 2005 and 2006. Cohort two (C2) 
consisted of 71 consecutive untreated CLL patients diagnosed between 2007 and 
2011. The principal characteristics of C1 and C2 are reported in Table 2.1. 
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2.2.4.2 FISH analysis on immunomagnetically sorted cells in patient C1 
In the 28 patients in C1, CD38+ and CD38- CLL cells were isolated by 
immunomagnetic sorting. The purity of sorted fractions was >98% as determined 
by flow cytometric analysis. For CLL risk assessment, FISH was performed in all 
patient on peripheral blood samples obtained at diagnosis using probes for 13q14, 
12q13, 11q22/ATM, 17p13/TP53. In C1 patients, FISH analysis was performed on 
both CD38+ and CD38- sorted cells, and the following region was investigated: 
13q14, 12q13, 11q22/ATM, 17p13/TP53 and 14q32. Co-hybridization experiments 
were performed in order to evaluate the coexistence on the same cells of more 
genetic lesions. 
 
TABLE 2.2. FISH results in CLL patients with detectable genetic lesions in CD38+ cells 
 
 
*biallelic 13q deletion. 
 
Result of FISH analysis in CD38- cells and CD38+ cells in C1 are reported in 




Age  mean yrs  (range) 65 (50‐91) 64 (38‐86)













les ions  in CD38+ cel ls Cohybridizations
56 13q del  (20%) 25 20 Neg 32 24 3 Different cel l s
58 13q del  (30%) 28 30 Neg 28 18 3 Different cel l s
41 Neg 23 24 Neg Neg 40 3 Different cel l s
50 13q del  (60%) 37 21 15 Neg 33 3 ND
46 13q del  (18%) 42 22 Neg Neg 3820 2 ND
49 13q del  (60%) 37 23 Neg 21 23 3 Different cel l s
61 Neg 33 26 Neg 22 Neg 3 Different cel l s
43 Neg 34 Neg Neg 27 Neg 2 Same  cel ls
56 Neg 19 Neg Neg 49 21 2 Different cel l s
63 Neg 20 (69*) Neg Neg Neg Neg 2 ND
45 13q del  (69%) 58 33 17 Neg Neg 2 Different cel l s
54 Neg 62* Neg Neg 18 Neg 2 Same  cel ls
60 Neg 18 Neg Neg Neg Neg 1 NA
48 13q del  (38%) 45 20 Neg Neg Neg 1 Different cel l s
57 13q del  (30%) 37 Neg 19 Neg Neg 1 ND
64 Neg 34 Neg 33 Neg Neg 1 Same  cel ls
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To assess whether the genetic lesions were on different clones, co-hybridization 
experiments using appropriate probes were performed in 11 cases with >1 
aberration in CD38+ cells. In these experiments it was shown that genetic lesions 
involved different CD38+ cells in 8 cases and involved the same cells in remaining  
3 cases. 
 
2.2.4.3 miRNA profiling on immunomagnetically sorted cells in C1 
MiRNA expression was investigated using Agilent Technologies platform. Samples 
were grouped according to the presence or not of genetic lesions by FISH analysis 
in the CD38 positive cells. So we evaluated the global miRNA expression profile of 
19 patients by considering CD38+ and CD38- cell populations separately.  
We found that at diagnosis most of the patients with genetic lesions in CD38+ (W) 
had a distinctive miRNA profile when compared to those without genetic lesions 
(WO), both in CD38+ (Fig. 2.1 A) and CD38- fraction (Fig. 2.1 B).  
Twenty-three miRNAs were found to be differentially expressed in CD38+ 
population (corrected p<0.05) and nine miRNAs were found to be differentially 
expressed in CD38- population (corrected p<0.05). Four miRNAs were found to be 
down-regulated in patients with in contrast to those without genetic aberrations in 
CD38+ cells, both in the CD38+ and CD38- subpopulations: let-7e-5p, miR-125a-
5p, miR-181b-5p and miR-338-3p. Interestingly, miR-125a-5p showed the higher 
degree of significance both in CD38+ and CD38- cell fractions and was therefore 
chosen for further clinical correlations. The down-regulation of miR-125a-5p was 
confirmed by RT-qPCR analysis, using Taqman MicroRNA assay specific for miR-
125a-5p and normalized on 18S ribosomal RNA. 
 
2.2.4.4 Clinical outcome 
In C1, the presence of additional FISH abnormalities in the CD38+ cells correlated 
with a more aggressive course of the disease that was characterized by a shorter 
time to treatment (TTT) (HR 8.052, range 1.332-16.760, p=0.0162) (Fig. 2.2 A). 
Having shown that miR-125a-5p down regulation was strongly associated with 
additional FISH lesions on CD38+ cells and with shorter TTT, we investigated in 
an independent cohort of 71 consecutive untreated low-risk CLL the clinical 
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SNV, non synonymous variation. 
 
2.3 THE PATHOGENETIC ROLE OF “PROLIFERATION CENTERS” 
IN CLL: SITES WITH CD38+ CELLS AND A HIGH FREQUENCY OF 
GENETIC INSTABILITY 
2.3.1 The role of microenvironment in CLL 
Available evidence exists suggesting that the interaction of leukemic cells with 
stromal and T cells in the microenvironment has a key role in CLL pathogenesis 
and evolution. As there is increasing evidence that individual cancer samples are 
heterogeneous and include subclonal populations and that tumors likely evolve 
through competition and interaction between different sublclones, this tumoral 
microenvironment appears to be the site where acquisition of additional genetic 
lesions in the clone occur, which, should greatly influence clinical outcome [92]. In 
this hypothesis CLL could emerged as a chronic disease in which the host 
physiologically provides essential elements and conditions leading to the 
acquisition and accumulation of genetic alterations by leukemic cells. This scheme 
accommodates the existence of structures that provide replicating and surviving 
signals to B cells on their way to neoplastic transformation [5, 10]. A key element 
in this view is that leukemic cells can and do proliferate, with division taking place 
not in the blood, but primarily in specialized morphologically discrete structures of 
lymph nodes and bone marrow known as proliferation centers (PCs) [66, 84, 93, 
94]. 
So important advances in the molecular pathogenesis were obtained through the 
study of the role of the microenvironment. 
CLL can be defined  as a low-grade CD5+ B-cell tumor, whose tumoral cells have 
previously encountered the antigen, escaped programmed cell death and 
undergone cell cycle arrest in the G0/G1 phase. In CLL cells, elevated levels of 
Patient Gene Chr Genomic pos ition Location Ref sequence Var sequence Mutation type Freq. %
1 DDX3X chrX 41204747 exonic GAAAGTAGTTTGGGTGGAAGA GAAAGTAGTT‐‐‐‐TGGAAGA Frameshi ft deletion 39,1
2 SF3B1 chr2 198267491 exonic C G SNV 52,7
3 MYD88 chr3 38182641 exonic T C SNV 10,8
4 TP53 chr17 7577575 exonic A C Stop codon 6,4
TP53 chr17 7577580 exonic T C SNV 18,9
5 XPO1 chr2 61719472 exonic C T SNV 26,3
6 ATM chr11 108138003 exonic T C SNV 64,1
FBXW7 chr4 153249384 exonic C T SNV 32,9
7 TP53 chr17 7578536 exonic T C SNV 28,6
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the cyclin-negative regulator p27-Kip1 protein are found in a minority of patients 
[95]. Given the key role of this protein in cell cycle progression, its overexpression 
in CLL cells may account for the accumulation of B cells in early phases of the cell 
cycle [96]. In addition, overexpression of the anti-apoptotic BCL-2, BCL-XL, BAG-1 
and MCL-1 molecules and the absence of microRNAs miR-15 and miR-16 [97], 
whereas proapoptotic proteins like BAX and BCL-XS are under expressed [98] 
could explain the resistance of tumoral cells to apoptosis. Despite the fact that 
most leukemic cells are arrested in cell cycle G0/G1 stages, Messmer et al. [83] 
demonstrated that CLL is not only a static disease but also a disease in which a 
proliferative pool coexist. In consequence, evolution of this leukemia depend on 
the relative balance between these subpopulations. 
In contrast with in vivo results, apoptosis occurs after in vitro culture, suggesting  a 
role of the microenvironment in CLL cell survival [99]. Within leukemic 
microenvironment, two cellular components appear to be potential players: stromal 
cells and T-lymphocytes. Direct contact between CLL and mesenchymal stromal 
cells (MSCs) is required for this inhibition of apoptosis, and tumor cell-stromal cell 
interactions are also important in controlling migration into and retention of CLL 
cells within tissue compartments (bone marrow or lymphoid tissue). MSCs are an 
important component of the bone marrow and support the maintenance of normal 
hematopoietic stem cells [100]. When co-coltured with CLL cells, MSCs have also 
been shown to protect the neoplastic B cells from apoptosis induced by 
fludarabine, bendamustine and steroids [101, 102]. Closely related to MSCs is a 
population of monocyte-derived “nurse-like” cells (NLC) that are also able to 
protect CLL cells from apoptosis [103, 104]. Both MSCs and NLCs therefore have 
anti-apoptotic activity and the combination of these two cell types provides a 
supportive microenvironment for tumor cells in CLL. In the other side, also T 
lymphocytes are attractive candidates to the role of elements that amplify 
microenvironment able to inhibit the malignant B-cell apoptosis and to favour 
disease progression. The weight of evidence points to a dialogue between CLL 
cells and CD4+ T cells, based upon bidirectional interactions that are regulated by 
adhesion molecules and chemokine and translate into the production of several 
cytokines by both cell types [99]. Many reports suggest that CD40/CD40L 
interactions are central to the dialogue between CLL cells and T cells. CD40 is a 
member of the tumor necrosis factor (TNF) receptor superfamily that is expressed 
by B cells, dendritic cells and monocytes [105]. CD40L is a member of the TNF 
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family expressed by activated T cells. The stimulation of CD40 rescues CLL cells 
from apoptosis and induces their proliferation [98, 106]. 
 
2.3.2 Proliferation centers 
At this time, it is clear that crosstalk with accessory cells in specialized tissue 
microenvironments favours disease progression by promoting malignant B-cell 
growth and the emergence of new genetic alterations, which will lead to drug 
resistance. Therefore, understanding the crosstalk between malignant B-cells and 
their milieu could give us new keys on the cellular and molecular biology of CLL 
that can finally lead to novel strategies for disease treatment. In this regard, the 
isolation and analyses of the tumoral subset that is being triggered in the 
proliferative compartments of progressive CLL cases is an important aim to 
understand CLL pathogenesis. 
The CLL proliferating compartment is represented by focal aggregates of 
proliferating prolymphocytes and para-immunoblasts that give rise to the so-called 
pseudofollicles or proliferation centers (PCs) [107]. Proliferation centres are 
present in approximately 90% of lymphocytic lymphomas. They are the histological 
CLL hallmark in lymph nodes, white pulp of the spleen and bone marrow where 
they appear as vaguely nodular areas never surrounded by a mantle zone. They 
consist of loosely arranged larger cells that often contain prominent nucleoli. In 
contrast to true B-cell follicle, which may be found entrapped within the small 
lymphocytic infiltrate in sections of B-CLL, proliferations centers are said not to 
contain follicular dendritic cells, although their presence has been occasionally 
recorded. Proliferation centers contain numerous T cells, most of which are CD4+. 
Notably, as compared to the non-proliferation center component of CLL, cells 
clustered in the proliferation centers have increased expression of the 
proliferation-associated markers Ki-67 and CD71, co-expression of survivin and 
BCL-2 and also higher expression of CD20, CD23 and MUM1/IRF-4 [81, 107]. 
Cells are surrounded by and interspersed with new vessels. It is still unclear 
whether these newly formed vessels are fully functional and bring nutrients to the 
proliferating cells or whether they represent an epiphenomenon of the 




Although the size of PCs and the amount of para-immunoblasts in lymph node 
sections did not show a correlation with clinical course [109, 110], the presence of 
more extensive PCs in follow-up biopsies has been reported [111]. Interestingly, a 
recent study suggested that an association may exist between the expanded and 
highly active PCs and an aggressive variant of CLL [112]. 
 
2.3.3 Tissue microarray 
Recently, techniques were developed that allow for the application of fluorescence 
in situ hybridization (FISH) on paraffine-embedded fixed tissues [113]. This 
technique is based on tissue microarray (TMA) [114]. It was first described by 
Kononen in 1998 [115], and represents  a high-throughput technology for the 
assessment of histology-based laboratory test, including immunohistochemistry 
and FISH. Small cylindrical cores are extracted from standard formalin-fixed, 
paraffin-embedded tissue and arranged in a matrix configuration within a recipient 
paraffin block. The TMA has proven to be invaluable in the study of tumor biology, 
the development of diagnostic tests and the investigation of oncological 
biomarkers. The preparation of tissue microarray for FISH analyses made this 
technique a potentially ideal method for the screening of large number of cases in 
a single hybridization experiment [114]. 
 
As only few data are available on the cytogenetic profile of lymph nodes in CLL 
and the presence of chromosome lesions in correlation with the extension of PCs 
has never been previously tested, we designed a study aiming to: 
- analyze the sensitivity and reproducibility of FISH on paraffin-embedded 
fixed tissues arranged on TMA from 183 consecutive lymph node biopsies 
corresponding to histologically ascertained CLL; 
- estimate the frequency of chromosome lesions on lymph node samples 
- analyze the possible correlation of specific chromosome lesions and the 
extension of PCs, and how these features may impact on clinical outcome. 
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(28/113), trisomy 12 19.5% (26/133) and 17p deletion 15.6% (23/147). There was 
no significant difference in the incidence of 13q-, +12, 11q- and 14q32 
translocations in untreated vs pretreated patients, whereas 17p- occurred more 
frequently in treated patients as compared with untreated ones (26% and 6.5% of 
the cases, respectively).  
A total of 79 out of 101 patients successfully analysed with the 5-probe panel 
(78.2%) showed at least one chromosomal aberration. Using a cytogenetic 
classification assigning every patient to a single category according to hierarchy 
17p- >11q- >14q32 >+12 >13q-, the 11q deletion was the most frequent 
cytogenetic anomaly accounting for 20% of the cases, followed by 17p- (17%), 
14q32/IGH translocation (16%), 13q- (15.8%) an trisomy 12 (11%). 
 
2.3.4.4 Histopathologic subtypes and their association with biologic features 
A total of 108/183 cases (59.1%) with scattered PCs were assigned to the typical 
subtype. A total of 75/183 cases (40.9%) were assigned to the PCs-rich subtype, 
owing to the presence of confluent PCs. 17p-, + 12 and 14q32/IGH translocation 
were more frequently encountered in the PCs-rich subtype than in the typical 
subtype (20/60 cases vs 3/87 for 17p-, p>0.001; 15/52 vs 11/81 for +12, p=0.030; 
and 22/54 vs 20/82 for 14q32 translocations, p=0.043). 
The sections were tested with anti-ZAP70 and anti-Ki-67. Ki-67 was positive in 
>30% of the cells in 27/164 cases successfully tested: 4/95 Ki-67+ cases belonged 
to the “typical” subtype as compared with 23/69 Ki-67+ CLL in the PCs-rich group 
(p<0.0001). ZAP70 was positive in 91/149 (61,1%) and there was no statistically 
signiﬁcant difference between cases classiﬁed as typical CLL and PCs-rich CLL. 
A thorough analysis of existing correlations between histological features and 
clinico-biologic parameters was performed in 101 patients with successful 
hybridization with the complete 5-probe panel (Table 2.4). 
IGHV usage in correlation with mutational status in 67 cases is shown in Figure 3. 
Rearranged IGHV families recurrently involved were as follows: IGHV1-69: 19.4%; 
IGHV3-30: 11.9%; IGHV3-7: 7.4%; IGHV3-23, IGHV3-48, IGHV4-34 and IGHV4-
39: 6% each. Others IGHV families were involved in 45% of the cases. As shown 
in Table 2.4, 17p-, 14q32/IgH translocations, +12 and ‘unfavourable’ FISH 
abnormalities (that is, 11q- and 17p-) were more frequently encountered in the 




TABLE 2.4. Clinical features and demographics of the 101 patients with cytogenetic data obtained 
with 5-probe panel. 
 
 
CI, confidential interval; FISH, fluorescence in situ hybridization; NS not significant. 
 
Likewise, Ki-67 positivity in >30% of cells, being pretreated at time of biopsy and 
longer interval between diagnosis and biopsy, were associated with the PCs-rich 
subtype, whereas no signiﬁcant association was noted between ZAP-70+, IGHV 










Age  (mean 63.9 (sd 10.4) 65.0 (sd 12.3) NS
Sex
   F 24 17 NS
   M 40 20
Stage  at time  of biopsy
   0‐2 27 15 NS
   3‐4 25 18
17p‐
   No 62 22 <0.001
   Yes 2 15
11q‐
   No 49 26 NS
   Yes 15 11
14q32/IgH trans locations
   No 50 18 0.002
   Yes 14 19
Trisomy 12
   No 53 25 0.021
   Yes 8 12
13q‐
   No 35 27 NS
   Yes 29 10
Unfavourable  FISH (11q‐ and/or 17p‐)
   No 48 16 0.001
   Yes 16 21
ZAP‐70+ (n=84)
   No 33 17 NS
   Yes 21 13
Ki67 (n=92)
   >30% 4 12 0.001
   <30% 53 23
IgHV (n=67)
   Unmutated 28 19 NS
   Mutated 14 6



























































































































































































TOWARDS A BETTER UNDERSTANDING OF THE PATHOGENESIS 
OF CLL: CELL ACTIVATION AND GENETIC INSTABILITY 
In CLL patients, there is evidence that a complex subclonal architecture of the 
leukemic clone may correlate with a more aggressive course of the disease and 
that in most cases genomic abnormalities are recurrent non-random events that 
expand over time due to a Darwinian selective pressure [89, 116]. Clinically, the 
existence of multiple, genetically distinct, subpopulations that escape therapeutic 
intervention presents formidable challenges for the development of effective 
treatment for patients with relapsed or refractory CLL. 
CD38 is a marker of unfavourable prognosis and an indicator of cell activation and 
proliferation that may prelude clonal evolution and worse clinical outcome [117]. 
Several reports suggest that patients with 7-30% CD38-positive leukemic cells 
exhibit a more aggressive disease course and have an inferior response to 
treatment. Grubor et al. [89] found clear evidence of intraclonal heterogeneity 
within patients, searching for genomic differences between CD38+ and CD38- 
populations in the same patient. Peppers et al. [91] demonstrated that CD38+ CLL 
cells possess a distinct gene expression profile when compared with CD38- 
subclones derived from the same patient. Because clonal members can be 
heterogeneous in expression of genes and markers related to cellular activation 
and adhesion, in particular CD38, this intraclonal heterogeneity may translate in 
differences that determine which cells enter the cell cycle. This finding suggest 
that the expression of the CD38 antigen defines a subpopulation of CLL cells with 
a distinct transcriptional profile that may be the cause or effect of an increase in 
cellular activation. 
We therefore studied the biological and clinical significance of the presence of 
genetic heterogeneity in the minor CD38+ leukemic population, in a cohort of 
untreated low-risk CLL patients as define by CD38 negativity (CD38+ cells < 7%) 
and low-risk FISH findings (normal or 13q deletion as sole abnormality). Our data 
showed that a significant proportion of CD38- CLL patients with low risk FISH 
findings presented genetic aberrations within CD38+ cells. Most of these 
abnormalities were high risk lesions (11q deletion in 9 cases, 17p deletion in 8 
cases) and in most of the cases these lesions were found in different cells 
indicating that multiple cytogenetically unrelated minor clones may be present in 
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the CD38+ cell fraction. The small size of the abnormal C38+ clones precluded the 
detection of these aberrations when analyzing by FISH the entire neoplastic 
population consisting of a majority of CD38- cells. Interestingly, the presence of 
these additional FISH lesions in the small CD38+ cell fraction was associated with 
shorter TTT. Genetic complexity and heterogeneity in the architecture of the 
leukemic clone was previously documented in CLL and was associated with 
disease progression and shorter TTT [118].  
To identify biomarkers associated with this phenomenon, we performed miRNA 
expression analysis because deregulation of miRNA was previously shown to be 
associated with activation markers [119]. By comparing C1 patients with and 
without small abnormal clones in the CD38+ fraction, we were thus able to show a 
deregulated miRNA expression profile in CLL cases with additional FISH lesions in 
CD38+ cells. In particular, miR-125a-5p was found to be down-regulated both in 
CD38+ and CD38- cells in patients with FISH abnormal clones as compared to 
patients without FISH abnormal clones. MiR-125a-5p was therefore chosen as a 
marker associated with genetic complexity and possibly with a more aggressive 
clinical behaviour as suggested by the shorter TTT that we observed in these 
patients. The relevance of miR-125a-5p as a biomarker of inferior outcome and 
genetic complexity was then validated in a prospective cohort of 71 consecutive 
untreated CD38- CLL patients with normal FISH or 13q deletion as single 
abnormality. In this validation cohort, we were able to confirm the predictive role of 
miR-125a-5p down-regulation in terms of shorter TTT. To our knowledge, this is 
the first observation linking a deregulated miRNA expression to inferior outcome in 
a subset of low risk CLL patients. This finding is valuable because the majority of 
CLL patients present with low risk features at diagnosis and disease progression is 
difficult to predict in such cases. In addition, in this validation cohort we found, 
through the use of NGS technology, that CLL patients with lower levels of miR-
125a-5p displayed an increased rate of mutations in CLL-related genes. 
Interestingly most of the mutations found in our patients, including TP53, SF3B1 
and ATM, have been associated with a worse clinical outcome and prognosis. This 
observation further strengthens the association between genetic complexity, miR-
125-5p down-regulation and worse outcome. Alterations in miRNA expression are 
involved in the initiation, progression, and metastasis of several human cancers, 
by acting both as tumor suppressors and oncogenes in cancer development [120]. 
In particular, miR-125a-5p was previously found to act as a non-organ specific 
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tumor suppressor gene that, when down-regulated, is associated, in several solid 
cancers, with a more aggressive course of the disease and a worse prognosis 
[121-123]. A germline mutation in mature miR-125a-5p has also been closely 
associated with breast cancer tumorigenesis [124]. This miRNA primarily achieves 
its antiproliferative effect through down-regulation of proliferation related genes, 
involved in the phosphoinositide-3 kinase (PI3K)- AKT and RAS/RAF/mitogen-
activated protein kinase signalling [121]. Noteworthy, it was recently shown that in 
SMZL, an indolent B cell lymphoproliferative disorder like CLL, there is a 
characteristic deregulation of miRNA expression including down-regulation of miR-
125a-5p with a possible implication in its molecular tumorigenesis [125]. By 
contrast, miR-125a was also found commonly gained and/or overexpressed in 
DLBCL [126] and in this perspective it would be interesting to look at miR-125a-5p 
levels in CLL patients that has transformed into Richter’s syndrome. 
To better understand the pathogenic role of membrane maker CD38, we put our 
attention on this molecule that supports B cell interactions and differentiation. 
Several recent studies have shown that CD38 expression is higher in CLL cells in 
the bone marrow and lymphoid tissues when compared to peripheral blood [93]. 
This implies that once CLL cells leave these compartments, they begin to lose 
CD38 expression and by inference, the higher the degree of renewal/turnover from 
bone marrow and lymph nodes [91]. Indeed CLL is a disease in which the host’s 
microenvironment promotes leukemic cell growth, leading to sequential acquisition 
and accumulation of genetic alterations [127]. In order to clarify this idea, an 
increasing body of data suggests that proliferative centers play an important role in 
the biology of CLL as they constitute its proliferative compartment [66, 128]. 
However the complexity of the microenvironment of proliferation centers has not 
been completely elucidated [128]. To better deﬁne the signiﬁcance of proliferation 
centers (PCs), the morphological hallmark of chronic lymphocytic leukemia (CLL), 
we studied lymph node biopsies taken from 183 patients by ﬂuorescence in situ 
hybridization (FISH) studies using a 5-probe panel on tissue microarrays (TMAs). 
As tissue biopsy is not mandatory for the diagnosis of CLL, few studies addressed 
the signiﬁcance of histological ﬁndings and the incidence of chromosomal 
aberrations at the tissue level in this setting. The TMA technology offers the 
possibility to analyze simultaneously a consistent number of cases thus reducing 
costs and experimental variability. The patient population was not representative 
of the entire CLL population seen at the referring centers during the study period, 
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because we included patients with progressive disease and clinically relevant 
adenopathy, and FISH analysis was performed in biopsies taken in different 
phases of the history of the disease. In line with these considerations, the IGHV 
usage in our cases showed frequent V1-69 gene involvement, mostly in the 
unmutated conﬁguration, a relatively low VH4-34, frequently found in mutated CLL 
[129], and very low incidence of other VH subtypes normally associated with 
indolent CLL or monoclonal B-cell lymphocytosis [129]. An unexpectedly high 12% 
incidence of V3-30 involvement was seen in our series. Unlike previous reports, 
describing V3-30 usage in association with mutated CLL running an indolent 
course [130, 131], 7/8 cases using V3-30 genes in this series lacked IGHV 
somatic mutations, suggesting that the mutational status might be an important 
determinant of outcome within speciﬁc IGHV families. The 78.2% overall incidence 
of chromosome lesions in our study using a 5-probe panel is in line with previous 
analyses performed on PB samples obtained from untreated and pretreated 
patients [15]. Caraway et al. [132] found abnormal FISH signal patterns in 81% of 
CLL cases on ﬁne-needle aspirates, and Flanagan et al. [133] described at least 
one cytogenetic aberration in all 18 patients analyzed on lymph node biopsy. 
Interestingly, while conﬁrming that the occurrence of 17p- was more common in 
relapsed CLL [134], other aberrations were found in our series to occur at a similar 
incidence in untreated and in treated patients. 11q deletion is usually associated 
with a disease characterized by marked lymphadenopathy [135]. As the incidence 
of 11q- may be higher in patients with therapy-demanding disease independent by 
previous treatments [60], the relatively high incidence of 11q- in our series (24.7%) 
may be accounted for by inclusion in this study of patients with clinically signiﬁcant 
adenopathy. A previously unreported ﬁnding was represented by a high incidence 
(30.8%) of 14q32/IgH translocations both in treated and in untreated patients. 
Three possible explanations may account for this observation: i) 14q32 
translocation may appear more frequently at the tissue level than in the PB, as 
previously suggested for trisomy 12 [136]; ii) 14q32 translocation may be 
associated with adenopathy and active disease requiring treatment, as suggested 
in two recent analyses [137, 138]; and iii) 14q32 translocation may represent in 
some of our cases a secondary anomaly acquired late during the course of the 
disease. Indeed, karyotype instability was detected in a fraction of CLL [139], and 
14q32/ IgH translocation may represent a late event in the progression of lymphoid 
neoplasias. Interestingly, recent analyses on a limited number of CLL patients 
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reported a 17–21% incidence for these translocations in lymph node samples 
[133], and 18 independent lymph node biopsies submitted to FISH analysis on 
isolated cell suspension in this study gave a 33% incidence for this aberration.  
The frequency of PCs-rich CLL in our series was 40.9%, and 14q32/IgH 
translocations, þ12 and 17p-, were signiﬁcantly associated with the PCs-rich 
group. Unfavorable cytogenetic features, such as 11q-/17p-, were more frequently 
encountered in the PCs-rich group than in the typical group. The presence of 
prominent PCs, which was associated with ki-67þ in our analysis, is thought to be 
an index of B-cell proliferation capability, which increases the risk that DNA 
replication errors could happen, thus predisposing the cell to the acquisition of 
sequential genetic damage. Likewise, ATM and p53 gene deletions impair the 
checkpoint cell machinery and render the cell more fragile to antigenic stimuli 
encountered at PCs level. These considerations may provide a biological basis to 
explain the strong unfavourable prognostic signiﬁcance of conﬂuent PC in CLL that 
was found in our study. Interestingly, Gine et al. [112] recently described a new 
histological category, that is, “accelerated” CLL, including 23 out of 78 (29.4%) 
cases with enlarged and conﬂuent PCs, with 42.4 mitosis per PCs and 430% Ki-67 
per PCs. This histological subset of CLL was associated with adverse biological 
features and inferior survival. Our data support and reinforce this view, in that they 
show that conﬂuent PCs are associated with adverse cytogenetics and represent 
the strongest prognostic factor.  
 
In conclusion, in order to clarify the pathogenetic process in CLL, we focus our 
attention on genetic heterogeneity reflected by membrane marker CD38. In our 
first mentioned study  (i) by FISH analysis we disclosed genetic lesions in the 
minor of CD38+ cell fraction in CD38- CLL with low-risk FISH findings, (ii) we 
provided evidence supporting an association between cryptic genetic lesions in 
CD38+ cells and disease progression, (iii) we found that genomic complexity and 
worse outcome were associated with miR-125a-5p down-regulation and, iv) we 
validated this finding in an independent cohort of untreated CD38- CLL patients 
with low risk FISH findings. This set of data show that genetic lesions may appear 
in CD38+ cells in low-risk CLL and that they may be associated with miR-125a-5p 
down-regulation, allowing for a more accurate prognostication in low-risk CLL. 
Aiming to the hypothesis that genetic instability origins into CLL microenvironment, 
we focused on lymph nodes, and in particular on proliferation centers, correlating 
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PCs pattern with clinico-biologic and cytogenetic characteristic. The association of 
PCs-rich pattern with unfavourable cytogenetics and short survival may support 
the pathogenetic role of proliferation center in CLL. As the patients included in this 
analysis represented an unselected cohort of CLL undergoing biopsy due to 
clinically signiﬁcant adenopathy, we found a high incidence of adverse biologic 
features, that is, unmutated IGHV conﬁguration, ZAP70, and high-risk 
cytogenetics. Our study demonstrated that the histopathological pattern deﬁned by 
the presence of conﬂuent PCs may represent an important feature for risk 
assessment in this subset of patients. This ﬁnding is important when considering 
that increasing awareness of the possible evolution into Richter’s syndrome is 
prompting clinicians to perform lymph node biopsy more often than in the past and 
that the therapeutic armamentarium in clinically aggressive CLL may include 
intensive chemoimmunotherapy and allogenic bone marrow transplantation from 




CHAPTER 3  




One of the clinical hallmarks of chronic lymphocytic leukemia (CLL) is the high 
degree of variability in its disease course. Whereas some patients experience an 
indolent disease course, others succumb to the disease rapidly despite intensive 
treatment. Over time, most patients develop refractory disease that does not 
respond to chemotherapy [4, 96]. Although the two major staging systems have 
provided valuable information in addressing this clinical heterogeneity, they have 
been unable to predict an indolent or aggressive course within the intermediate 
risk category [7, 8]. Several clinical and biological prognostic factors have been 
identiﬁed, such as speciﬁc cytogenetic alterations [140], mutational status of 
immunoglobulin (Ig) genes and the expression level of CD38 [67] and ZAP70 
[141]. The implication of these biological predictor factors with the molecular 
pathogenesis of the CLL is still under investigation, and an eventual therapeutic 
application is not yet developed. The recognition of novel molecular variables 
identified through the use of high-throughput molecular analytical techniques could 
contribute to a better knowledge of the disease pathogenesis, the development of 
more accurate biological predictive factors, the adjustment of therapies to the 
specific risk, and the identification of new therapeutic targets in CLL.  
CLL turned out to be a disease with multiple facets in its pathogenic mechanisms 
including genetic aberrations, antigen drive and microenvironmental interactions. 
In the first part of this work, we focused our attention on the role of 
microenvironment in CLL pathogenesis and, in particular, on the modality by which 
the cell membrane marker CD38 reflects genetic instability and heterogeneity. At 
this point we aimed to translate this knowledge in clinical practice focusing i) on 
the correlation between clonal evolution and development of chromosomal 
aberrations and ii) on how to stratify patients at diagnosis according to cytogenetic 
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aberrations, 13q14 deletions may be heterozygous (monoallelic in 76% of cases) 
or homozygous (biallelic in 24% of cases). Studies of serial samples suggest that 
heterozygous deletion is an early event, whereas deletion of the second copy of 
this region occurs at later stage [144, 145]. 
Patients with losses on 13q14 as the only aberration, based on FISH data, show a 
favourable prognosis; however, recent studies indicate that the situation may be 
more complex, suggesting that the percentage of interphase nuclei with deletions, 
as well as the size of the deletion, could influence the outcome [15]. 
Various groups have attempted to identify a tumor suppressor gene in 13q. No 
inactivation of candidate genes by mutation has been demonstrated, but a 
complex epigenetic regulatory tumor suppressor mechanism that controls the 
expression of the whole region has been described [146]. In a crucial study, Calin 
and co-workers showed that 13q14 deletion in CLL is associated with down-
regulation of miR-15a and miR-16-1, whose genes cluster in the minimally deleted 
region (MDR) within 13q14 [147]. The miR-15a/16-1 cluster was deleted or down-
regulated in the majority of CLL cases (68%) and seems to negatively regulate the 
expression of BCL2 and several other genes involved in proliferation and 
apoptosis [97, 148, 149]. Subsequent murine studies in which the specific miR-
15a/16-1 cluster was deleted have led to the development of monoclonal B cell 
lymphocytosis and CLL with low penetrance [149]. 
 Trisomy 12. Trisomy 12 is among the most frequent aberrations in CLL, 
occurring in 10-20% of cases. It has long been associated with early progression 
[15]. Initial FISH studies have suggested that the outcome was intermediate for 
this group. Recent analysis of prospective trials suggests that although 
progression-free survival (PFS) may be shorter, OS is favourable [49]. Cases with 
trisomy 12 rarely show TP53 mutations and rarely acquire these over time [150]. 
Trisomy 12 has been associated with an atypical morphology or 
immunophenotype [151]. A minimal common gained region has been confined to 
12q13, small duplications of 12q have been reported and MDM2 gene, which is 
located at 12q15, is amplified in CLL [152]. Moreover CLLU1, which is located at 
12q22, has been proposed as a prognostic marker in patients <70 years of age, 
since its higher level of expression has been associated with shorter OS [153], 
although over-expression of CLLU1 occurs irrespective of trisomy 12 [154]. The 
critical genes involved in this aberration, therefore, remain unknown. 
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 11q-. Approximately one-fifth of patients with treatment indications exhibit 
11q deletions, and ATM mutations have been reported in 30% of patients with 
del(11q). Patients with an 11q deletion are generally younger, have more B-
symptoms and a more rapid progression of the disease, and shorter OS [135]. 
Furthermore, the aberration is typically associated with extensive 
lymphoadenopathy [4]; however, it has been recently reported that de novo 11q 
deleted CLLs can exhibits variable clinical outcome [155]. There is a very strong 
association between the presence of the deletion 11q and unmutated IgHV 
mutation status [25]. The biological basis for this association is currently unclear. 
The minimal consensus region in bands 11q22.3-q23.1 harbors the ATM gene in 
almost all cases. The ATM protein kinase is a central component of the DNA 
damage pathway and mediates cellular responses to DNA double-strand breaks 
[156]. ATM activates cell cycle checkpoints, can induce apoptosis in response to 
DNA breaks and functions directly in the repair of DNA double-strand breaks. 
 17p-. Del(17p) has been described in 3-8% of patients who are naïve to 
treatment, although higher occurrences of up to 30% have been reported in 
patients with advanced, relapsed disease [15, 157]. About 80-90% of cases with 
deletion of one copy of the TP53 locus will have mutation on the remaining copy 
[158]. Very few cases with 17p deletion will have a functional p53 pathway. This 
aberration is usually associated with a very aggressive clinical course and is 
predictive of lower PFS, lack of response to therapy, short response duration and 
short OS [15, 159].  
The deletion always contains the TP53 locus but usually covers most of the short 
arm of chromosome 17, which has prompted a consideration of other genes that 
might be targeted by this deletion. The tumor suppressor p53 plays an essential 
role in inducing apoptosis or cell cycle arrest after DNA damage. Therapy with 
fludarabine and alkylating agents is based on a p53-dependent mechanism, which 
could explain why CLL patients with del17 or inactivating mutations of TP53 are 
refractory to such chemotherapy [143]; however, fludarabine refractoriness is 
caused by TP53 disruption in approximately 40% of CLL patients who did not 
respond to treatment, but, in a sizeable fraction, the molecular basis of this 
aggressive clinical phenotype still remains unknown [158, 160, 161]. Current 
treatment approaches take advantage of the growing number of drugs with 
documented effectiveness independent of functional p53. A more specific or 
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targeted option for this subgroup of patients is the identification of drugs targeting 
mutant p53, which could be effective in this CLL subgroup. 
 6q-. Deletion of the long arm of chromosome 6 is a rare cytogenetic 
abnormality seen in approximately 6% of CLL patients [15, 162, 163]. It is 
generally considered an intermediate-risk feature, since it is associated with more 
prominent lymphocytosis with atypical morphology, splenomegaly, higher rates of 
CD38 positivity, and no association with IGHV mutation status [162]. 
 Translocations. Recurrent balanced translocations are rare in CLL, in 
contrast to other types of leukemia or B cell lymphomas in which specific and 
recurrent translocations deregulate known oncogenes [15, 164, 165]. 
Translocations involving immunoglobulin genes are the most common recurrent 
translocations in CLL, although they have only been observed in <5% of cases. 
Recurrent partners include BCL2, BCL3, BCL11A and c-MYC, although unknown 
partner genes are also frequent [137]. Chromosomal translocations generally have 
a negative effect on response to therapy and survival, especially when 
unbalanced. Unbalanced non-reciprocal aberrations are frequent and often seen in 
complex karyotypes. 
 Complex karyotype. Although CLL is characterized by relatively stable 
genome and most CLL cases appear to carry few genomic aberrations, a high 
number of CNAs (>3 per patient), termed genomic complexity, is detected in a 
proportion of CLL patients (~20%). Genomic complexity demarcates a CLL subset 
with progressive and aggressive disease, short survival, and decreased 
therapeutic efficacy [166, 167]. 
 
 3.2.1 Clonal evolution in CLL 
In 1985, Nowell et al. stated that karyotypic evolution is rare in B-CLL [168]. Its 
occurrence indicates a poor prognosis, but its rarity suggests that clinical 
progression in this disease is usually more dependent on other factors. Despite 
these claims, clonal evolution (CE) was more recently reported in 15-42% of CLLs 
using conventional karyotyping or fluorescence in situ hybridization [139, 145, 
169]. The incidence of this phenomenon is variable, depending on the length of 
follow up [145] and on the number of probes used for FISH analyses [170]. CE 
was defined by the late appearance of aberrations of chromosome 17p, 11q, 6q 
and 12. Shanafelt et al. reported that 27% of CLL patients developed new 
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cytogenetic abnormalities at chromosome sites of known prognostic importance 
during the course of their disease [145]. Patients with high ZAP-70 expression 
seem to be more likely to experience such clonal evolution and to acquire 
unfavourable cytogenetic abnormalities. In another study, despite the limited case 
number, clonal evolution was identified as an independent prognostic factor for 
overall survival and it only occurred in CLL with unmutated IGHV genes indicating 
to karyotypic instability as a pathomechanism [139]. Basically, CE is associated 
with markers of active disease, i.e. ZAP70 positivity and unmutated IGHV gene. 
Besides the classical CLL-associated aberrations [15, 165], other recurring 
changes have been described in CLL [171], and attention was recently devoted to 
14q32 translocations involving the immunoglobulin heavy chain gene (IGH). This 
aberrations was found in 6-19% of patients with CLL at diagnosis [165], and was 
associated with advanced stage disease, unmutated IGHV genes, CD38 positivity 
and need therapy [137, 138]. 
 
The incidence of this aberration at clonal evolution was unknown. To better define 
the incidence and the significance 14q32/IGH translocations occurring at CE, we 
performed this study including 105 cases of CLL analysed sequentially over a 10-
year period with panel of probes including an IGH break-apart probe.  
Details are shown in Appendix III (paper Cavazzini F et al, Leukemia & Lymphoma 
2012). 
 
3.2.2 Methods and results 
3.2.2.1 Patients  
105 cases of CLL, seen at our institution between 1995 and 2004, were included 
in this study, after making sure that fulfilled the following criteria: 
- Diagnosis of CLL based on morphology and immunophenotyping (score 
Matutes ≥3 [172]) 
- Successful FISH analysis at diagnosis and during follow-up 
- Clinical records available for review. 
Patients were submitted to FISH analyses as part of routine diagnostic work-up. 
FISH was repeated on at least one occasion in all 105 patients. Sequential 
samples were obtained before each line of treatment and 4-6 years intervals in 
those not requiring treatment. 
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Diagnosis was based on the presence of persistent lymphocytosis (>5.000/µl), on 
examination of peripheral blood (PB) smear and on the results of 
immunophenotyping. The following markers were tested in all cases by 
cytofluorimetric analysis, using 30% cut-off for positivity in the lymphocyte gate: 
CD5, CD19, CD23, CD22, CD10 antigens; the FMC7 monoclonal antibody and the 
expression of surface immunoglobulins were also tested. The co-expression of 
CD38 and CD19 antigens was tested with a 30% cut-off for positivity. As a rule, 
trephine biopsy was performed in young patients (<60 years of age). Histological 
studies were performed for diagnostic purposes in selected cases. Patients were 
treated according to guidelines in use at our institutions during the study period. 
Fludarabine containing regimens were used as front-line treatment in young 
patients and in refractory or relapsing patients. Intermittent chlorambucil 
administration was used as first-line therapy in the majority of elderly patients (<70 
years). 
 
3.2.2.2 Clonal evolution 
Sequential FISH studies were performed on peripheral blood (PB) samples using 
commercially available probes for the identification of deletions at 13q14/D13S25, 
11q23/ATM, 17p13/TP53, trisomy 12 and translocations at 14q32/IGH. Sensitivity 
limit for the detection of 14q32 translocation, trisomy 12 and deletions were >3%, 
>3% and >8% interphase cells with split signal, three signals and one signal, 
respectively. The following probes were used in patients with 14q32/IGH 
translocation to identify the partner chromosome: 11q14/BCL1, 18q21/BCL2, 
3q27/BCL6, 18q21/MALT1 and 8q24/MYC. Non-commercial bacterial artificial 
clones (BACs) were also used for 2p12/BCL11A, 6p21/CCND3, 19q13/BCL3, 
7q21/CDK6 and for the evaluation of the region 5p15.31-33. 
Those patients with 11q- and/or 17p- were considered as “high cytogenetic risk” 
and the remaining patients with 13q-, +12 or 14q32/IGH translocations were 
considered as “standard cytogenetic risk”. 
The median interval between diagnosis and first FISH analysis was 2 months 
(range 1–12 months). CE was observed in 15/105 patients after 24–170 months, 
median 64, as detailed in Table 3.1. Recurring aberrations at clonal evolution were 
14q32/IGH translocation in seven patients; 17p- in four patients, 11q- in two 
patients, biallelic 13q- in four cases, hemizygous 13q- in one case and 14q32 
deletion in one patient. A 17p deletion was associated with 14q32/IGH 
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rearrangement in 3/7 patients (patients 1, 2 and 6), one of whom also developed a 
biallelic 13q14 deletion (patient 6). In two cases with 14q32/IGH translocation at 
CE (patients 1 and 7), a paired BM or lymph node (LN) sample and PB samples 
were available for FISH studies. In these patients the appearance of IGH 
translocation in the BM or the LN sample preceded its appearance in PB samples 
(Table 3.1) by 13–58 months. The 14q32/IGH translocation persisted at 
subsequent analyses in both cases. All patients with the 14q32/IGH translocation 
were assessed by interphase FISH for the detection of possible chromosome 
partners. Three out of seven cases (cases 2, 5 and 6) showed an IGH–BCL2 
fusion signal consistent with a t(14;18)(q32;q21) translocation. In the remaining 
four cases it was not possible to identify the partner chromosome with our probe 
panel. 
 




3.2.2.3 Correlation between CE, 14q32/IGH translocations, hematologic and 
clinical parameters  
Forty-seven patients did not require treatment throughout the study period and 58 
patients received 1–6 lines of  treatment. CE was detected in 15 pre-treated 
patients, seven of whom had a 14q32/IGH translocation, after 1–4 lines of 
treatment (median 3). In contrast none of 47 untreated patients developed CE (p 
<0.0001), as shown in Table 3.2, where the patients’ characteristics at initial 
evaluation are presented in detail.  
ZAP70+ and high-risk cytogenetics predicted for the occurrence of CE with 
borderline statistical significance, p<0.055 and 0.07, respectively (Table 3.2); no 
Patient
Aberrations  at diagnos is  








1 13q‐ bia l lel ic (42%) 13q‐ bia l lel i c (55%); IgH R (18%)*; 17p‐ (27%) 2 60
2 No aberration 17p‐ (26%); IgH R (21%) (IGH‐BCL2) 1 58
3 11q‐ (20%) 11q‐ (26%); IgH R (20%) 1 73
4 13q‐ (21%) 13q‐ (53%); IgH R (19%) 3 91
5 +12 (28%) +12 (42%); IgH R (16%) (IGH‐BCL2) 4 64
6 13q‐ (32%); 11q‐ (15%) 13q‐ bia l lel i c (34%);11q‐ (27%); IgH R (21%) (IGH‐BCL2); 17p‐ (18%) 4 74
7 +12 (30%) +12 (55%); IgH R (25%)* 3 51
8 No aberration 11q‐ (42%) 4 41
9 No aberration 17p‐ (54%) 4 97
10 No aberration 11q‐ (61%) 3 48
11 13q‐ (66%); 11q‐ (65%) 11q‐ (61%); 13q‐ bia l lel i c (60%) 5 84
12 +12 (56%) +12 (51%); 13q‐ (71%) 3 87
13 No aberration 13q‐ bia l lel i c (71%) 3 53
14 13q‐ (78%) 13q‐ bia l lel i c (67%) 5 170
15 No aberration 14q32 deletion (45%) 2 24
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other baseline hematologic characteristic predicted for CE and for the late 
appearance of 14q32/IGH translocations. 
 




*p<0.0001; **p=0.014; ***p=0.016; ****p=0.027. 
CLL, chronic lymphocytic leukemia; FISH, Fluorescence in situ hybridization; CE, clonal evolution. 
 
TABLE 3.3. Correlation of outcome measures and development of CE. 
 
 
CE, clonal evolution; TFT, Time to first treatment; TTCR, Time to chemorefractoriness; ns, not 
significant. 
Characteris tic












Median age, years  (range) 63 (31‐86 63 (31‐86) 63 (51‐78) 63 (31‐86) 60 (51‐71)
M/F ratio 66/39 57/33 09‐giu 62/36 04‐mar
Lymphocytes
   <30 x 10^9/L 89 78 11 84 5
   >30 x 10^9/L 16 12 4 14 2
Rai  s tage
   0‐1 84 74 10 80 4
   2‐4 21 16 5 18 3
CD38+
   Negative 72 64 8 69 3
   Pos i tive 30 23 7 26 4
ZAP70
   Negative 46 40 5 42 4
   Pos i tive 25 17 8 22 3
FISH aberrations
   Standard ri sk 92 81 11 87 5
   High ri sk 13 9 4 11 2
Treated before  CE
   Yes 58 43 15* 51 7**
   No 47 47 0 47 0
Relapsed/refractory
   Yes 27 16 11*** 21 6****
   No 31 27 4 30 1
Outcome  measure Months p‐Value
TFT
   Al l  patients  (n=105) 54
   With CE (n=15) 35 0.0033
   Without CE (n=90) 71
   With 14q32 trans locations  (n=7) 36 0.067
   Without 14q32 trans locations  (n=98) 63
TTCR
   Al l  patients  (n=58) 72
   With CE (n=15) 34 0.0046
   Without CE (n=43) 86
   With 14q32 trans locations  (n=7) 27 0.0002
   Without 14q32 trans locations  (n=51) 75
Survival  form diagnos is
   Al l  patients  (n=105) 173
   With CE (n=15) 124 ns
   Without CE (n=43) 173
   With 14q32 trans locations  (n=7) 125 ns













































































































































































TABLE 3.4. Impact of baseline characteristics on TTCR in 58 treated patients. 
 
 
TTCR, Time to chemorefractoriness; SE, standard error. 
 
3.2.3 Conventional karyotyping using novel mitogens 
Cytogenetic aberrations play an important role as prognostic factors in CLL. Due 
to the low mitotic index of CLL B cells in vitro, analysis of a set of the most 
commonly known aberrations is usually done by FISH on interphase cells, which 
detects aberrations in about 80% of CLL samples [15]. The use of metaphase 
cytogenetics, which provides an unsupervised insight into the chromosomal 
aberrations of a specific sample, has been limited in CLL because of technical 
issues. Even though 90% of patient samples could be evaluated cytogenetically, 
aberrations could be detected in only 40% to 50% of cases [140], in contrast to 
FISH analysis. It is presently not clear whether other aberrations that are not 
detected by the standard FISH panel have any impact on prognosis and disease 
progression. Therefore, an approach to generate high-quality metaphases in CLL 
still would be highly desirable.  
The B-cell mitogen CD40-ligand (CD40L) was previously compared to 
conventional mitogens for metaphase induction in CLL, and these results were 
compared with those from standard FISH analysis [164, 173]. CD40L stimulation 
induced metaphases in 93% of cases, versus 78% with conventional methods 
[173]. Even more important, CD40L stimulation resulted in the detection of 
aberrations in 89% of cases versus only 22% by conventional methods and 
confirmed all aberrations detected by FISH [173]. In addition, so-called complex 





   M (n=38) 72 7.8 0.95
   F (n=20) 86 19.7
Stage
   0‐2 (n=47) 86 8.7 0.0004
   3‐4 (n=11) 27 6.1
CD38
   Negative  (n=34) 75 8.1 0.0857
   Pos i tive  (n=23) 48 3.5
ZAP70
   Negative  (n=28) 72 15.1 0.34
   Pos i tive  (n=21) 58 9.5
Cytogenetics  at diagnos is




the need for a labor-intensive, cellular coculture system, CD40L-enhanced 
cytogenetics is hardly applicable for routine diagnostics. 
Dicker et al. [174] presented a method for the efficient induction of metaphases in 
CLL B cells. This method relies on the addition of the immunostimulatory 
oligonucleotide DSP30 plus IL-2 as a CLL B-cell–specific mitogen to the cultures, 
which was originally developed for immunotherapeutic applications [175, 176]. In 
contrast to earlier reports on metaphase cytogenetics in CLL that employed 
different B-cell mitogens such as TPA, lipopolysaccharide, and others, here they 
generated metaphases for a successful analysis in 95% of all CLL samples that 
were subjected to the DSP30/IL-2 culture. More importantly, aberrations could be 
detected by chromosomal banding in more than 80% of these samples, a number 
that is similar to FISH analysis and that shows an almost 2-fold increase relative to 
earlier studies. 
 
In order to better understand the significance of chromosome aberrations in CLL 
patients with relatively favourable outcome, we designed a study to assess 
whether karyotypic aberrations in patients without FISH anomalies (here referred 
to as “normal” FISH) correlate with established clinical and prognostic parameters. 
The clinical and prognostic significance of karyotypic aberrations in normal FISH 
CLL was first evaluated in a retrospective single centre series of patients and then 
validated prospectively in a multicentre series of cases diagnosed and analysed 
for karyotype with DPS30/IL2 stimulation.  
Details are shown in Appendix IV (paper Rigolin GM et al, Blood 2012). 
 
3.2.4 Methods and results 
3.2.4.1 Patients 
We first evaluated a retrospective series of patients (learning cohort, LC) that 
consisted of 65 out of 70 unselected “normal” FISH CLL patients for whom a 
successful cytogenetic analysis was available, derived form a series of 218 
consecutive CLL diagnosed between 1998 and 2006. Then we validated in 
prospective series of 85 normal FISH patients, with successful cytogenetic 
analysis and derived from a series of 274 consecutive CLL diagnosed at 4 centres 
between 2007 and 2011. Only patients with a score Matutes ≥3 [172] were 
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included. The expression of CD38 and ZAP-70 were tested on fresh peripheral 
blood cells with a 20% cut-off for positivity. 
 
3.2.4.2 Comparison between conventional kayotyping and FISH analyses 
In the LC cytogenetic analyses was performed using traditional mitogens. In the 
VC cytogenetic analyses was centralized in the Ferrara centre and performed 
using CpG-oligonucleotide DSP30 plus IL2. In all cases cytogenetic analysis was 
conducted on the same samples used for FISH studies. Interphase FISH was 
performed on peripheral blood samples obtained at diagnosis or before therapy 
using probes for the following regions: 13q14, 12q13, 11q22/ATM, 17p13/TP53. 
An abnormal karyotype was observed in 14/65 (21.5%) and 30/84 (35.7%) 
patients of LC and VC, respectively. A significant proportion of CLL cases with 
normal FISH carry chromosome aberrations in regions not covered by the 4-probe 
FISH panel commonly used [15]. An abnormal karyotype was found in 6.4% and 
10.9% of normal FISH cases in the LC and in the VC, respectively. Recurring 
aberrations were: 14q deletions, 7q deletions, 6q deletions, 14q32 translocations, 
3q deletions. A complex karyotype (≥3 aberrations) was found in 14 patients, 12 of 
which in the VC. 
This study confirms previous observations that in CLL patients stimulation with 
DSP30/IL2 improves the rate of metaphase generation (65/70 vs 85/85 cases in 
the LC and VC, respectively, p=0.017) 
 
3.2.4.3 Correlation between karyotype and clinicobiological parameters, and 
TFT analyses 
The correlations between karyotype and clinicobiological parameters are reported 
in Table 3.5. Interestingly, the abnormal karyotype did not correlate with known 
molecular prognostic parameters, including CD38 and ZAP-70 positivity (in both 
LC and VC), and IgHV mutational status in the VC. By mutational analysis we 
observed no TP53 mutations in the VC (0 out of 23 patients with abnormal 
karyotype). Time to first treatment (TTT) was calculated as the interval between 
diagnosis and the start of first line therapy. Overall survival (OS) was calculated 
form the date of diagnosis until death due to any cause or until the last patient 
follow-up. In CLL patients with “normal” FISH the abnormal karyotype significantly 
correlated with a shorter TTT in univariate analysis in both the LC and the VC 
(Table 3.5, Figure 3.2). At multivariate analysis, the factors independently 
60 
 
predictive of shorter TTT were: in the LC: CD38 positivity (HR 2.82, 95% CI 1.19-
6.69, p=0.018) and abnormal karyotype (HR 2.54, 95% CI 1.07-6.07, p=0.034); in 
the VC: advanced Binet stage (HR 2.77, 95% CI 1.05-7.29, p=0.039,) and 
abnormal karyotype (HR 6.39, 95% CI 2.44-16.86, p<0.001). The abnormal 
karyotype also correlated at univariate analysis with OS in both the LC and the VC 
(HR 5.87, 95% CI 2.08-62.68, p=0.005, and HR 9.41, 95% CI 1.61-47.35, 
p=0.0119 respectively, Figure 3.3) 
 
TABLE 3.5. Learning and validation cohorts: clinical correlations according to karyotype and 
analysis of factors affecting TFT. 
 
 
nd, not done; ns, not significant; HR, hazard ratio. 
 
 















   Mean (range) 64 (31‐84) 69 (50‐87) ns 63 (41‐90) 63 (32‐84) ns
Sex
   M/F n. of pts 31/20 8/6 ns 34/20 23/7 ns
Matutes  score
   3/4/5 n. of pts 3/25/23 4/3/7 0.030 4/24/25 7/6/12 0.035
Binet Stage
   A/B/C n. of pts 47/3/1 10/3/1 0.089 45/9/0 20/7/3 0.040
CD38
   pos/neg n. of pts 21/29 8/6 ns 11/41 12/18 0.079
ZAP70
   pos/neg n. of pts 15/6 5/4 ns 16/31 15/11 0.083
IgHV
   unmutated/mutated n. of pts nd nd 11/38 10/17 0.191
Therapy








   Abnormal  vs  Normal 14 vs  51 3.33      
(2.03‐15.66)




   B‐C vs  A 8 vs  57 4.56      
(4.43‐89.97)




   pos  vs  neg 29 vs  35 3.26      
(1.60‐7.78)




   pos  vs  neg 10 vs  20 2.31      
(0.81‐5.78)




























































































































































have been identified through the application of whole genome/exome sequencing 
to CLL, and, beside their contribution to leukemic transformation, a number of 
observations point to mutations of these genes as attractive biomarkers of 
potential clinical relevance. Alterations of these genes occur in approximately 5-
10% of CLL patients at diagnosis and have shown significant correlations with 
survival [28, 30, 177]. 
 
NOTCH1. Among the genes mutated in CLL, NOTCH1 emerged as a 
recurrently targeted by genetic lesions in specific phases of the disease. NOTCH1 
encodes a ligand-activated transcription factor that regulates several down-stream 
pathways important for cell growth control and is affected by activating mutations 
in 60% of T-lineage acute lymphoblastic leukemia [178]. In CLL, the frequency of 
NOTCH1 mutations at the time of diagnosis is approximately 10% [26-28]. 
NOTCH1 mutations at CLL diagnosis preferentially occur among unmutated CLL 
and cluster with trisomy 12 [26-28, 179, 180] . NOTCH1 mutations identify a high-
risk subgroup of patients showing poor survival comparable to that associated with 
TP53 abnormalities and exert a prognostic role that is independent of widely 
accepted risk factors, as confirmed in multiple consecutive series from different 
institutions [26-28]. One recurrent mutation (c.7544_7545delCT) accounts for 
approximately 80% of all NOTCH1 mutations [26-28] and can be rapidly detected 
by a simple PCR-based approach, providing a potential strategy for a first level 
screening of NOTCH1 alterations [28]. Although the precise role of NOTCH1 
activation in CLL pathogenesis is still unclear, the relevance of these mutations is 
highlighted by the distinctive GEP signature of CLL carrying NOTCH1 mutations 
[26, 180]. 
SF3B1. SF3B1 is a core component of the splicing machinery, which 
catalyses the removal of introns from precursor messenger RNA (mRNA) to 
produce mature mRNA [181]. At diagnosis, SF3B1 is mutated in 5-10% of CLLs 
[29, 177, 182]. The pathogenicity of SF3B1 mutations in CLL is supported by the 
clustering of these mutations in evolutionary hotspots localized within HEAT 
domain (codon 662, 66, 700, 704 and 742) [29, 177, 182]. Although the precise 
mechanistic aspects of SF3B1 mutations are still under investigation, the 
observation that SF3B1 regulates the alternative splicing program of genes 
controlling cell cycle progression and apoptosis points to a potential contribution of 
SF3B1 mutations in modulating tumor cell proliferation and survival [29, 182]. At 
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CLL diagnosis, SF3B1 mutations predict reduced survival independent of other 
clinical and biological risk factors, and show a preferential association with CLL 
showing 11q22-q23 deletion and ATM mutations [29, 177, 182]. 
BIRC3. BIRC3, along with TRAF2 and TRAF3, cooperates in the same 
protein complex that negatively regulates MAP3K14, an activator of the non-
canonical pathway of NF-kB signalling [183]. The BIRC3 gene is recurrently 
disrupted in CLL by mutations, deletions or a combination of mutations and 
deletions [30]. BIRC3 lesions are rare in the early phases of the disease, where 
they mark poor prognosis, while they accumulate in progressive and refractory 
CLL [30]. Identification of BIRC3 involvement in CLL may be important for 
elucidating the molecular genetics of 11q22-q23 deletion. In fact, although ATM 
has been regarded as the relevant gene of this cytogenetic lesion, biallelic 
inactivation of ATM does not exceed 30% of CLL with 11q22-q23 deletion. On the 
basis, a second tumor suppressor in the 11q22-q23 region has been postulated 
along with ATM. The BIRC3 gene, that maps on 11q22.2 might represent an 
attractive candidate. 
MYD88. In B-cells, Toll-like receptors (TLRs) are central to the BCR-
independent response to antigens by sensing a variety of pathogen associated 
molecular patterns [184]. After stimulation of TLRs, MYD88 is recruited, as 
cytoplasmic adaptor, to the activated receptor complex as a homodimer and form 
proteins complexes that trigger activation of NF-kB [184]. The most prevalent 
mutation in CLL is the L265P missense substitution that occurs in ~3% of cases 
[26, 29, 182]. Among biological subgroups of CLL, MYD88 mutations are enriched 
among cases harboring mutated IgHV genes and 13q14 deletion as the sole 
cytogenetic abnormality [185]. 
TP53. The tumor suppressor gene TP53 maps on the short arm of 
chromosome 17 (17p13) and codes for a central regulator of the DNA-damage-
response pathway. Activation of TP53 leads to cell-cycle arrest, DNA repair, 
apoptosis, or senescence via both transcription-dependent and transcriptional-
independent activities. Consistently, TP53 plays a central role in mediating the 
pro-apoptotic and antiproliferative action of several DNA-damaging 
chemotherapeutic agents, including alkylators and purine analogs [186]. 
In CLL, the TP53 gene may be inactivated by deletion and/or somatic mutations 
[23, 150]. Most cases with 17p13 deletion also carry TP53 mutations on the 
second allele (~60%), while the remaining cases have monoallelic 17p13 deletion 
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remarkable speed [188]. Massive parallel sequencing technology provides a 
means of systematically discovering the genetic alterations that underlie disease 
and identifying new therapeutic targets and clinically predictive biomarkers. Since 
the launch of first NGS platform, a number of technological advances have been 
made, such as improved sequencing chemistry and novel signal detection 
methodologies [189]. This has resulted in the availability of the new small NGS 
systems as well as Ion Torrent Personal Genome Machine (PGM). Ion Torrent is a 
sequencer that uses semiconductor sequencing technology. It bases the 
sequencing process on the detection of the change in pH resulting from H+ ion 
release upon nucleotide incorporation.  PGM uses a high-density array of micro 
wells to perform sequencing and beneath the wells is an ion sensitive layer 
followed by a proprietary ion sensor which detects changes in pH resulting from 
release of hydrogen ion following nucleotide incorporation. Fragments to be 
sequenced are captured on beads and amplified by emulsion PCR. The beads are 
then deposited in the microwell such that each well has only one bead carrying a 
unique amplified fragment. Nucleotides are then added in a predetermined 
sequence to the wells. A nucleotide complementary to the nucleotide in the 
fragment being sequenced gets incorporated in the strand being synthesized and 
a hydrogen ion is released. Upon release of hydrogen ion, the voltage of the 
solution changes in that well and is detected by the ion sensor. If two nucleotides 
are incorporated in a cycle, then the voltage is doubled and the sensor records two 
nucleotides added. If a nucleotide is not added during a cycle then no voltage 
change is recorded. It is the first commercial sequencing machine that does not 
require fluorescence and camera scanning, resulting in higher speed of analysis 
and lower cost [190]. 
 
In order to improve understanding of genetic basis of CLL and to apply NGS by 
Ion Torrent technology to CLL, we sequenced DNA samples from 28 untreated 
patients affected by chronic lymphocytic leukemia and we correlated mutational 
status with clinicobiological parameters. 






3.3.2 Methods and results 
3.3.2.1 Patients 
Twenty-eight  untreated cases of CLL seen at our institution between 2006 and 
2008 were included in this study. The principal clinical characteristics of the 
patients are reported in Table 3.6. Diagnosis was made according to standard NCI 
criteria [4]. Indications for treatment included: increased WBC count with <6 month 
lymphocyte doubling time, anemia or thrombocytopenia due to bone marrow 
infiltration or autoimmune phenomena not responding to steroids, disease 
progression in the Binet staging system. Fludarabine-containing regimens were 
used as first-line treatment; chlorambucil was used in some elderly and unfit 
patients. At diagnosis, immunophenotypic analysis was performed according to 
NCI criteria [4]. Immunophenotyping with a standard diagnostic panel including 
anti CD38 monoclonal antibodies was performed as previously reported [137, 
191]. The expression of CD38 were tested, as described [192], on fresh peripheral 
blood (PB) cells with a 20% cut-off for positivity. 
 




The patients were classified in 3 cytogenetic risk categories: 17p-, 11q- or complex 
karyotype defined the high risk group, +12 or 1-2 cytogenetic aberrations defined 
the intermediate risk group, isolated 13q- or absence of detectable aberrations 
defined the low risk group. 
 
3.3.2.2 Cytogenetic analysis 
FISH studies were performed as previously reported [137, 191]. Conventional 
karyotyping was performed using ODN and IL2 as previously reported [192]. 
Results of FISH and cytogenetic analysis are reported in Table 3.7. In 14/28 
cases, FISH studies revealed genetic lesions. 17p deletion was seen in 2 cases, 
11q deletion in 1 case, trisomy 12 in 4 cases and 13q deletion in 9 cases.  
N of patients 28
Age mean yrs (range) 62 (49-75)
M/F 18/10
Stage (Binet) A/B/C 22/4/2
CD38 (>20%) neg/pos 20/7
IgVH Mutated/Unmutated 17/11
FISH Low /Intermediate/High 21/4/3
Karyotype Low /Intermediate/High 15/8/5
CLINICAL AND BIOLOGICAL CHARACTERISTICS
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In two cases, the 13q14 deletion was associated respectively to the deletion of 




































































































































































































































































































































































































































































































































































































































































































































































































































































































 19/28 cases showed an abnormal karyotype by conventional cytogenetic analysis, 
including 5/15 cases without detectable lesions by FISH (see Table 3.7). A 
complex karyotype (≥3 aberrations) was found in 4 cases. 
 
3.3.2.3 Mutational analysis by Next Generation Sequencing (NGS) 
NGS analysis was performed using Ion Torrent PGM. Libraries of spot exonic 
regions of 20 genes (ATM, BIRC3, BRAF, CDKN2A, CTNNB1, DDX3X, FBXW7, 
KIT, KLHL6, KRAS, MAPK1, MYD88, NOTCH1, NRAS, PIK3CA, POT1, SF3B1, 
TP53, XPO1, ZMYM3) were constructed using Agilent Haloplex Target Enrichment 
kit starting from genomic DNA. Enriched libraries linked to Ion Sphere Particles 
were loaded in one Ion chip and sequenced using Ion Torrent PGM, according to 
manufacturer instructions. Genomic segments analysed are reported in Table 3.8. 
Using Ion Torrent technology, somatic mutations were identified in 12 (42.8%) 
cases, as reported in Table 3.7. Mutations were found in a range from 6.4 to 
76.5% of the reads analysed. Each segment had a number of reads > 500. 
5 cases showed mutations in the TP53 gene in 6.4%-46. 8% of the reads, 3 cases 
presented POT1 mutations, while mutations of MYD88, FBXW7, MAPK1, DDX3X, 
KLHL6, SF3B1, KRAS and ATM were detected in  1 case each. 8 cases presented 
one mutated gene and 4 cases 2 mutated genes (TP53 in association with POT1 
or DDX3X, ATM in association with KLHL6 and KRAS with POT1) (Table 3.7). 
Gene mutations found were validated using capillary Sanger sequencing (Fig. 3.5) 
 
3.3.2.4 Correlation between mutational status and clinicobiological 
parameters 
The time to first treatment (TTT) was calculated as the interval between diagnosis 
and the start of first-line treatment. Survival curves were compared by using the 
log-rank test. A P value <.05 was used as a criterion for statistical significance. 
The correlations between mutational status and clinico-biological parameters are 













Chromosome Gene Start genomic position End genomic position Analyzable region
chr2 XPO1 61719173 61719706  "NC_000002.11:61719173-61719706"
chr2 SF3B1 198267115 198267848  "NC_000002.11:198267115-198267848"
chr2 SF3B1 198266411 198267036  "NC_000002.11:198266411-198267036"
chr2 SF3B1 198265215 198265916  "NC_000002.11:198265215-198265916"
chr15 CHD2 93499516 93499959  "NC_000015.9:93499516-93499959"
chr15 CHD2 93510384 93511033  "NC_000015.9:93510384-93511033"
chr15 CHD2 93534475 93535000  "NC_000015.9:93534475-93535000"
chr15 CHD2 93540268 93540784  "NC_000015.9:93540268-93540784"
chr15 CHD2 93555303 93555804  "NC_000015.9:93555303-93555804"
chr15 CHD2 93552180 93552765  "NC_000015.9:93552180-93552765"
chrX DDX3X 41196436 41196991  "NC_000023.10:41196436-41196991"
chrX DDX3X 41204135 41205040  "NC_000023.10:41204135-41205040"
chrX ZMYM3 70461788 70462292  "NC_000023.10:70461788-70462292"
chrX ZMYM3 70460768 70461442  "NC_000023.10:70460768-70461442"
chrX ZMYM3 70472711 70473246  "NC_000023.10:70472711-70473246"
chrX ZMYM3 70469561 70470208  "NC_000023.10:70469561-70470208"
chr17 TP53 7576768 7577268  "NC_000017.10:7576768-7577268"
chr17 TP53 7577349 7577687  "NC_000017.10:7577349-7577687"
chr17 TP53 7577851 7578801  "NC_000017.10:7577851-7578801"
chr17 TP53 7579055 7579834  "NC_000017.10:7579055-7579834"
chr4 KIT 55595386 55595769  "NC_000004.11:55595386-55595769"
chr4 KIT 55602365 55602872  "NC_000004.11:55602365-55602872"
chr4 FBXW7 153249048 153249593  "NC_000004.11:153249048-153249593"
chr4 FBXW7 153245138 153245696  "NC_000004.11:153245138-153245696"
chr4 FBXW7 153246985 153247682  "NC_000004.11:153246985-153247682"
chr4 FBXW7 153258767 153259117  "NC_000004.11:153258767-153259117"
chr3 MYD88 38182079 38182867  "NC_000003.11:38182079-38182867"
chr3 CTNNB1 41265794 41266469  "NC_000003.11:41265794-41266469"
chr3 PIK3CA 178951808 178952299  "NC_000003.11:178951808-178952299"
chr3 KLHL6 183272884 183273632  "NC_000003.11:183272884-183273632"
chr22 MAPK1 22126949 22127493  "NC_000022.10:22126949-22127493"
chr22 MAPK1 22159919 22160421  "NC_000022.10:22159919-22160421"
chr9 NOTCH 139390287 139391047  "NC_000009.11:139390287-139391047"
chr1 NRAS 115256330 115256815  "NC_000001.10:115256330-115256815"
chr1 NRAS 115258445 115258986  "NC_000001.10:115258445-115258986"
chr7 POT1 124498740 124499390  "NC_000007.13:124498740-124499390"
chr7 POT1 124510738 124511207  "NC_000007.13:124510738-124511207"
chr7 POT1 124532174 124532633  "NC_000007.13:124532174-124532633"
chr7 POT1 124538031 124538662  "NC_000007.13:124538031-124538662"
chr7 POT1 124536926 124537435  "NC_000007.13:124536926-124537435"
chr7 BRAF 140452990 140453495  "NC_000007.13:140452990-140453495"
chr11 BIRC3 102201521 102202174  "NC_000011.9:102201521-102202174"
chr11 BIRC3 102207344 102207768  "NC_000011.9:102207344-102207768"
chr11 ATM 108119490 108120023  "NC_000011.9:108119490-108120023"
chr11 ATM 108117519 108118136  "NC_000011.9:108117519-108118136"
chr11 ATM 108123199 108123716  "NC_000011.9:108123199-108123716"
chr11 ATM 108137735 108138170  "NC_000011.9:108137735-108138170"
chr11 ATM 108154862 108155488  "NC_000011.9:108154862-108155488"
chr11 ATM 108173355 108173950  "NC_000011.9:108173355-108173950"
chr11 ATM 108170161 108170733  "NC_000011.9:108170161-108170733"
chr11 ATM 108172302 108172703  "NC_000011.9:108172302-108172703"
chr11 ATM 108180579 108181241  "NC_000011.9:108180579-108181241"
chr11 ATM 108200697 108201254  "NC_000011.9:108200697-108201254"
chr11 ATM 108205463 108206084  "NC_000011.9:108205463-108206084"
chr11 ATM 108206442 108206939  "NC_000011.9:108206442-108206939"
chr11 ATM 108204378 108204828  "NC_000011.9:108204378-108204828"
chr11 ATM 108217938 108218252  "NC_000011.9:108217938-108218252"
chr11 ATM 108225292 108225744  "NC_000011.9:108225292-108225744"
chr11 ATM 108235751 108236396  "NC_000011.9:108235751-108236396"
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thought to be an infrequent phenomenon. CLL may undergo CE, with late 
appearance of 11q deletion, 17p deletion and 6q deletion in 16–17% of cases 
[139, 145]. Although recent evidence has been provided by several groups that the 
14q32/IGH translocation may identify a cytogenetic group of patients with CLL 
characterized by therapy-demanding disease [137, 138], scant information is 
available as to its possible appearance as a secondary abnormality in CLL. Fifteen 
out of 105 cases (14.3%) studied by FISH showed CE in our study, and seven of 
these 15 cases showed a 14q32/IGH translocation. The presence of 14q32/IGH 
translocation was previously documented to involve a minority of interphase cells 
in some patients with CLL [137], and one case was described as harboring IGH 
translocations with different partners [193]. These findings argue in favor of a 
possible secondary nature of this translocation in some patients. Interestingly, in 
our series the appearance of a 14q32 translocation in BM and LN samples 
preceded its appearance in the PB in two cases. Recent studies, included our 
work on proliferation centers, indicated that CLL cells in lymph nodes and bone 
marrow may have an important role in tumor proliferation [83, 92] and, 
interestingly, a relatively high incidence of 14q32/IGH translocation (17–19%) was 
noted by Flanagan and co-workers who performed FISH studies on paraffin-
embedded lymphoid tissue from CLL/small lymphocytic lymphoma (SLL) [133]. 
Because our patients were seen over a 10-year period, treatment was 
heterogeneous, and a comparison of treatment regimens in patients with and 
without CE was not performed; nevertheless, it is worth noting that in our seven 
patients with 14q32/IGH translocations at CE the median number of previous 
treatment lines was 3 (range 1–4), and that all patients received ≥1 cycle 
containing alkylating agents. Interestingly, IGH translocation accounted for 20% of 
the interphase cells (range 16–25%) in our study, and was associated with a minor 
clone carrying 17p deletion in three cases and 13q14 biallelic deletion in one. 
These data taken together suggest that genetic instability deriving from previous 
treatment might have played a role in the emergence of minor clones carrying a 
14q32/IGH translocation in our series. The late appearance of loss of chromosome 
material at 14q32 in one patient in this study parallels an observation by Shanafelt 
and co-workers [145]. Deletion affecting the chromosome 14q32 locus was 
previously described in CLL at a frequency of approximately 2–8% [194, 195]. 
Clonal evolution in CLL was demonstrated to be associated with unfavourable 
biological features in previous analyses, although no difference in overall survival 
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was noted between patients with and without CE [139]. In our series the 
development of CE occurred only in previously treated patients. By analyzing 
possible associations between CE and measures of clinical outcome we were able 
to show that TTT was shorter in patients who developed CE. This finding may be 
accounted for by the consideration that CE may reflect genetic instability, a feature 
normally associated with disease evolution prompting the appearance of resistant 
clones.  
In order to better understand the significance of chromosome aberrations in CLL 
patients and in particular in those patients with relatively favourable outcome, we 
designed a study to assess whether karyotypic aberrations in patients without 
FISH anomalies correlate with established clinical and prognostic parameters. 
Our data show that a significant proportion of CLL cases with normal FISH carry 
chromosome aberrations in regions not covered by the 4-probe FISH panel used 
in most clinical trials [15]. This novel cytogenetic category (i.e. abnormal karyotype 
with “normal” FISH) accounted for 8.9% in the pooled series of 492 patients of this 
study, thus representing the 4th most common cytogenetic group, following 
deletions at 13q and 11q, and trisomy 12. Recurring aberrations were 14q 
deletions, 7q deletions, 6q deletions, 14q32 translocations and 3q deletions. A 
complex karyotype (≥ 3 aberrations) was found in 14 patients. This study confirms 
previous observations that in CLL patients stimulation with DSP30/IL2 improves 
the rate of metaphase generation [174]. Interestingly, the abnormal karyotype did 
not correlate with known molecular prognostic parameters, including CD38 and 
ZAP 70 positivity, and IGHV mutational status. Most important we could 
demonstrate, for the first time, that among CLL patients with “normal” FISH the 
abnormal karyotype significantly correlated with a shorter TTT in univariate 
analysis. At multivariate analysis, the factors independently predictive of shorter 
TTT were: CD38 positivity, abnormal karyotype and advanced Binet stage. 
Recently it was demonstrated that, in CLL, TP53 mutations [158] represent a 
strong prognostic marker. By mutational analysis we observed no TP53 mutations 
in our patients. This finding is not surprising if we consider that patients with 17p- 
were excluded from this analysis and that, among untreated CLL without 17p-, the 
incidence of TP53 mutations is around 3% [20, 158, 160]. The abnormal karyotype 
also correlated at univariate analysis with OS. This observation needs to be 
validated in clinical trials with homogeneous treatment on larger series of patients.  
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The advent of next-generation sequencing (NGS), with its unprecedented ability to 
systematically discover key genetic alterations that underlie cancer, offers the 
tantalizing possibility of unraveling the genetic basis of this heterogeneity [196]. 
We applied this knowledge to CLL, developing a next-generation sequencing 
approach to screen 28 CLL patients at diagnosis in a custom-made panel of 20 
genes. The panel was designed to cover coding sequence of CLL involved genes 
according to recent literature [26, 28-30, 182]. We found somatic mutations in 12 
cases. TP53 was most frequently mutated (5 cases) and the frequency of 
mutations involving the other genes investigated was in line with data published in 
literature using whole exome sequencing [26, 29]. The percentage of reads 
showing mutation ranged from 6.4 to 76.5%. From the variability in the reads 
where mutation was found, we deduce that both clonal and subclonal mutations 
were present. The mutational profile of CLL can be characterized in two main 
group: clonal mutations, which are present in all tumor cells and represent early 
events in the leukemogenesis, and subclonal mutations, usually present in a small 
fraction of leukemic cells and possibly may represent progression events. This 
finding may explain the basis of the great heterogeneity within the CLL population 
[118]. ATM mutation present in the 76.5% of the reads analyzed is probably a 
predominantly clonal, whereas mutation with rates of 6-20% are probably 
subclonal mutations, that could expand over the time and lead to disease 
progression. 
Among our 19 cases with genetic lesions by FISH and/or cytogenetic analysis 
NGS showed gene mutations in 9 cases, documenting that cytogenetic, FISH and 
sequencing may represent complementary methods that allow to detect genetic 
heterogeneity within CLL. NGS could also provide information in a significant 
proportion of CLL patients with favorable prognostic features. Our method allow for 
the identification of genetic lesions in 25% of patients with non-informative 
cytogenetic analysis (FISH and karyotype) and 50% of FISH negative cases. In 
the three cases without cytogenetic and FISH abnormalities, we found mutated 
FBXW7, MAPK1 and TP53, respectively. Data are not surprising, in fact TP53 
mutations in the absence of 17p13 deletion are detected in 30% of CLL at 
diagnosis [150]. 
We then correlated mutational status with clinico-biological parameters. 
Interestingly, the presence of mutations correlated with high risk FISH (11q- and/or 
17p-) and unfavourable cytogenetic (11q-, 17p- or complex karyotype) findings. No 
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correlations were instead observed with other parameters like sex, age, 
Binet stage, CD38 and IGHV. The mutational status also correlated at univariate 
analysis with time to first treatment, that was significantly shorter in patients 
harboring somatic mutations. At multivariate analysis, no variable independently 
predictive of shorter TTT was statistically significant. This data is probably due to 
small number of patients analysed. Definitely a future goal will be to expand the 
series of patients. 
 
In conclusion, our data show that the 14q32/IGH translocation may represent one 
of the most frequent aberrations acquired during the natural history of CLL, and 
that it may be detected earlier in BM or LN samples. CE occurs in pretreated 
patients with short TTT, and survival after the development of CE with and without 
14q32 translocation is relatively short.  
To reassess the importance of cytogenetic analysis, we studied by conventional 
karyotyping using DSP30/IL2 stimulation a series of patients without FISH lesions. 
We were able to confirm that DSP30/IL2 stimulation is an effective method for the 
detection of chromosome aberrations in CLL, by documenting the presence of 
chromosome aberrations in approximately one third of CLL with “normal” FISH on 
a conventional 4-probe panel. This set of data also showed that, in CLL patients 
with “normal” FISH, conventional cytogenetic analysis identifies a subset of cases 
with adverse clinical and prognostic features to be considered for the design of 
risk-adapted treatment strategies. After examining these CLL cases with a novel 
technique of conventional karyotyping, we wanted to deepen our understanding of 
the molecular abnormalities by analyzing a CLL series with a next-generation 
sequencing technique. NGS by Ion Torrent might represent an important tool for 
the characterization of CLL genetic heterogeneity and clinical prognostic outcome. 
Ion Torrent is surely feasible due to the low cost and the short time for reaction. 
This techniques expanded our knowledge on the molecular mechanisms involved 
in the pathogenesis of the disease and offer new perspectives for prognostic 










In order to better understand the pathogenetic process in CLL, we focused our 
attention on genetic heterogeneity in the disease. In our first study  we provided 
evidence supporting an association between cryptic genetic lesions in CD38+ cells 
and disease progression and we found that genomic complexity and worse 
outcome were associated with miR-125a-5p down-regulation. This set of data 
show that genetic lesions may appear in CD38+ cells in low-risk CLL and that they 
may be associated with miR-125a-5p down-regulation, allowing for a more 
accurate prognostication in low-risk CLL. To assess whether genetic instability is 
more pronounced in microenvironment, we studied sequential lymph nodes 
samples, and we established a correlation between the extension of PCs and 
clinico-biologic as well as cytogenetic characteristic. The association of PCs-rich 
pattern with unfavourable cytogenetics and short survival may support the 
pathogenetic role of proliferation center in CLL. We found a high incidence of 
adverse biologic features, that is, unmutated IGHV conﬁguration, ZAP70, and 
high-risk cytogenetics in those patients with enlarged PCs. Our study 
demonstrated that the histopathological pattern deﬁned by the presence of 
conﬂuent PCs may represent an important feature for risk assessment in this 
subset of patients. 
To establish a correlation between genetic lesions and outcome we then focused 
on the correlation between clonal evolution (CE) and development of 
chromosomal aberrations. Our data showed that the 14q32/IGH translocation may 
represent one of the most frequent aberrations acquired during the natural history 
of CLL, and that it may be detected earlier in BM or LN samples. CE occurs in 
pretreated patients with short TTT, and survival after the development of CE with 
and without 14q32 translocation is relatively short. 
To improve the prognostic predictivity of cytogenetic analysis in the clinical 
practice, we studied by conventional karyotyping using novel mitogens (i.e. DSP30 
+ IL2 stimulation) a series of patients without detectable FISH lesions. We were 
able to confirm that DSP30/IL2 stimulation is an effective method for the detection 
of chromosome aberrations in CLL, by documenting the presence of chromosome 
aberrations in approximately one third of CLL with “normal” FISH. This set of data 
also showed that, in CLL patients with “normal” FISH, conventional cytogenetic 
analysis identifies a subset of cases with adverse clinical and prognostic features 
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to be considered for the design of risk-adapted treatment strategies. After 
examining these CLL cases with a novel technique of conventional karyotyping, 
we elected to further improve our capability to detect genetic lesions by analyzing 
a CLL series with a next-generation sequencing technique. Mutated patients 
showed a significant shorter median time to first treatment in comparison to those 
without mutations. This techniques expanded our knowledge on the molecular 
mechanisms involved in the pathogenesis of the disease and offer new 
perspectives for prognostic stratification and clinical management of the CLL 
patients. 
 
In conclusion, in this work we tried to arrive to a better understanding of the 
pathogenesis of CLL, through the study of cell activation and genetic instability. 
We have documented that genetic lesions may appear in a small fraction of 
leukemic clones in low-risk CLL and that they may be associated with a microRNA 
down-regulation. Then we have identified some genetic lesions associated more 
frequently with CE and with CLL showing adenopathy and confluent PCs. Finally, 
to translate this knowledge in clinical practice, we assessed prognosis with 
modern molecular techniques and we identified cytogenetic and molecular 
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